Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 435 articles:
HTML format
Text format



Single Articles


    January 2018
  1. KONDILI LA, Gaeta GB, Ieluzzi D, Zignego AL, et al
    Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.
    PLoS One. 2018;13:e0190803.
    PubMed     Text format     Abstract available


  2. CHARRE C, Cotte L, Kramer R, Miailhes P, et al
    Hepatitis C virus spread from HIV-positive to HIV-negative men who have sex with men.
    PLoS One. 2018;13:e0190340.
    PubMed     Text format     Abstract available


  3. CHEN SH, Lai HC, Chiang IP, Su WP, et al
    Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C.
    PLoS One. 2018;13:e0190455.
    PubMed     Text format     Abstract available


  4. BOLOTIN S, Feld JJ, Garber G, Wong WWL, et al
    Population-based estimate of hepatitis C virus prevalence in Ontario, Canada.
    PLoS One. 2018;13:e0191184.
    PubMed     Text format     Abstract available


  5. CHENG CH, Lin CC, Chen HL, Lin IT, et al
    Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection.
    PLoS One. 2018;13:e0191799.
    PubMed     Text format     Abstract available


  6. DEL CAMPO JA, Garcia-Valdecasas M, Gil-Gomez A, Rojas A, et al
    Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy.
    PLoS One. 2018;13:e0191805.
    PubMed     Text format     Abstract available


  7. NDJOYI-MBIGUINO A, Kombe Kombe AJ, Bivigou-Mboumba B, Zoa-Assoumou S, et al
    Low prevalence of HCV infection with predominance of genotype 4 among HIV patients living in Libreville, Gabon.
    PLoS One. 2018;13:e0190529.
    PubMed     Text format     Abstract available


  8. SAFREED-HARMON K, Hetherington KL, Aleman S, Alho H, et al
    Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study.
    PLoS One. 2018;13:e0190146.
    PubMed     Text format     Abstract available


  9. ZAHR NM
    Peripheral TNFalpha elevations in abstinent alcoholics are associated with hepatitis C infection.
    PLoS One. 2018;13:e0191586.
    PubMed     Text format     Abstract available


  10. KELLY ML, Riordan SM, Bopage R, Lloyd AR, et al
    Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study.
    PLoS One. 2018;13:e0192763.
    PubMed     Text format     Abstract available


  11. ANADOL E, Lust K, Boesecke C, Schwarze-Zander C, et al
    Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients.
    PLoS One. 2018;13:e0191118.
    PubMed     Text format     Abstract available


  12. RATTANAVIPAPONG W, Anothaisintawee T, Teerawattananon Y
    Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis.
    PLoS One. 2018;13:e0193112.
    PubMed     Text format     Abstract available


  13. TARAMASSO L, Di Biagio A, Bovis F, Nicolini LA, et al
    Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir +/- ribavirin in HIV/HCV co-infected patients.
    PLoS One. 2018;13:e0192627.
    PubMed     Text format     Abstract available


  14. CHENG PN, Chiu YC, Chiu HC, Chien SC, et al
    The characteristics of residents with unawareness of hepatitis C virus infection in community.
    PLoS One. 2018;13:e0193251.
    PubMed     Text format     Abstract available


  15. MAPOURE NY, Budzi MN, Eloumou SAFB, Malongue A, et al
    Neurological manifestations in chronic hepatitis C patients receiving care in a reference hospital in sub-Saharan Africa: A cross-sectional study.
    PLoS One. 2018;13:e0192406.
    PubMed     Text format     Abstract available


  16. MAUNOURY F, Clement A, Nwankwo C, Levy-Bachelot L, et al
    Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
    PLoS One. 2018;13:e0194329.
    PubMed     Text format     Abstract available


  17. DI POTO C, He S, Varghese RS, Zhao Y, et al
    Identification of race-associated metabolite biomarkers for hepatocellular carcinoma in patients with liver cirrhosis and hepatitis C virus infection.
    PLoS One. 2018;13:e0192748.
    PubMed     Text format     Abstract available


  18. MOTOYAMA H, Tamori A, Kubo S, Uchida-Kobayashi S, et al
    Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
    PLoS One. 2018;13:e0194163.
    PubMed     Text format     Abstract available


  19. ZEKRI AN, El-Sisi ER, Youssef ASE, Kamel MM, et al
    MicroRNA Signatures for circulating CD133-positive cells in hepatocellular carcinoma with HCV infection.
    PLoS One. 2018;13:e0193709.
    PubMed     Text format     Abstract available


  20. CARABALLO CORTES K, Rosinska M, Janiak M, Stepien M, et al
    Next-generation sequencing analysis of a cluster of hepatitis C virus infections in a haematology and oncology center.
    PLoS One. 2018;13:e0194816.
    PubMed     Text format     Abstract available


  21. NEMOZ B, Roger L, Leroy V, Poveda JD, et al
    Evaluation of the cobas(R) GT hepatitis C virus genotyping assay in G1-6 viruses including low viral loads and LiPA failures.
    PLoS One. 2018;13:e0194396.
    PubMed     Text format     Abstract available


  22. LI CW, Yang CJ, Sun HY, Tsai MS, et al
    Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan.
    PLoS One. 2018;13:e0194149.
    PubMed     Text format     Abstract available


  23. DES JARLAIS DC, Cooper HLF, Arasteh K, Feelemyer J, et al
    Potential geographic "hotspots" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US.
    PLoS One. 2018;13:e0194799.
    PubMed     Text format     Abstract available


  24. TI L, Socias ME, Wood E, Milloy MJ, et al
    The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs.
    PLoS One. 2018;13:e0194162.
    PubMed     Text format     Abstract available


  25. YAMAZAKI T, Joshita S, Umemura T, Usami Y, et al
    Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.
    PLoS One. 2018;13:e0195632.
    PubMed     Text format     Abstract available


  26. GOLIZEH M, Melendez-Pena CE, Ward BJ, Saeed S, et al
    Proteomic fingerprinting in HIV/HCV co-infection reveals serum biomarkers for the diagnosis of fibrosis staging.
    PLoS One. 2018;13:e0195148.
    PubMed     Text format     Abstract available


  27. FACENTE SN, Grebe E, Burk K, Morris MD, et al
    Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.
    PLoS One. 2018;13:e0195575.
    PubMed     Text format     Abstract available


  28. LU Y, Jin X, Duan CA, Chang F, et al
    Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naive patients in China.
    PLoS One. 2018;13:e0195117.
    PubMed     Text format     Abstract available


  29. HAMADA K, Saitoh S, Nishino N, Fukushima D, et al
    Shear wave elastography predicts hepatocellular carcinoma risk in hepatitis C patients after sustained virological response.
    PLoS One. 2018;13:e0195173.
    PubMed     Text format     Abstract available


  30. MASHIBA T, Joko K, Kurosaki M, Ochi H, et al
    Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
    PLoS One. 2018;13:e0194704.
    PubMed     Text format     Abstract available


  31. FISHER KA, Cahill LM, Broyles S, Rorke M, et al
    Knowledge of hepatitis C status moderates the relationship between history of drug treatment and sterile syringe use.
    PLoS One. 2018;13:e0196157.
    PubMed     Text format     Abstract available


  32. WASITTHANKASEM R, Vichaiwattana P, Siripon N, Posuwan N, et al
    Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    PLoS One. 2018;13:e0196301.
    PubMed     Text format     Abstract available


  33. OKUBO H, Ando H, Sorin Y, Nakadera E, et al
    Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C.
    PLoS One. 2018;13:e0196747.
    PubMed     Text format     Abstract available


  34. JIMENEZ-SOUSA MA, Gomez-Moreno AZ, Pineda-Tenor D, Medrano LM, et al
    The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design.
    PLoS One. 2018;13:e0197115.
    PubMed     Text format     Abstract available


  35. MAWATARI S, Oda K, Tabu K, Ijuin S, et al
    The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.
    PLoS One. 2018;13:e0198642.
    PubMed     Text format     Abstract available


  36. NAKANO T, Moriya K, Koike K, Horie T, et al
    Hepatitis C virus core protein triggers abnormal porphyrin metabolism in human hepatocellular carcinoma cells.
    PLoS One. 2018;13:e0198345.
    PubMed     Text format     Abstract available


  37. BLANCO RY, Loureiro CL, Villalba JA, Sulbaran YF, et al
    Decreasing prevalence of Hepatitis B and absence of Hepatitis C Virus infection in the Warao indigenous population of Venezuela.
    PLoS One. 2018;13:e0197662.
    PubMed     Text format     Abstract available


  38. GROTTENTHALER JM, Werner CR, Steurer M, Spengler U, et al
    Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
    PLoS One. 2018;13:e0197544.
    PubMed     Text format     Abstract available


  39. ZUCKERMAN A, Douglas A, Nwosu S, Choi L, et al
    Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era.
    PLoS One. 2018;13:e0199174.
    PubMed     Text format     Abstract available


  40. HAINSWORTH SW, Dietze PM, Wilson DP, Sutton B, et al
    Hepatitis C virus notification rates in Australia are highest in socioeconomically disadvantaged areas.
    PLoS One. 2018;13:e0198336.
    PubMed     Text format     Abstract available


  41. YEN YH, Kuo FY, Kee KM, Chang KC, et al
    APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level.
    PLoS One. 2018;13:e0199760.
    PubMed     Text format     Abstract available


  42. YAYA I, Roux P, Marcellin F, Wittkop L, et al
    Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.
    PLoS One. 2018;13:e0199874.
    PubMed     Text format     Abstract available


  43. SCHAEFER B, Viveiros A, Al-Zoairy R, Blach S, et al
    Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030.
    PLoS One. 2018;13:e0200750.
    PubMed     Text format     Abstract available


  44. FACENTE SN, Grebe E, Burk K, Morris MD, et al
    Correction: Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.
    PLoS One. 2018;13:e0200866.
    PubMed     Text format     Abstract available


  45. MIOTTO N, Mendes LC, Zanaga LP, Lazarini MSK, et al
    All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response.
    PLoS One. 2018;13:e0199941.
    PubMed     Text format     Abstract available


  46. TIEU HV, Laeyendecker O, Nandi V, Rose R, et al
    Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City.
    PLoS One. 2018;13:e0200269.
    PubMed     Text format     Abstract available


  47. SOOD A, Suryaprasad A, Trickey A, Kanchi S, et al
    The burden of hepatitis C virus infection in Punjab, India: A population-based serosurvey.
    PLoS One. 2018;13:e0200461.
    PubMed     Text format     Abstract available


  48. CUYPERS L, Perez AB, Chueca N, Aldamiz-Echevarria T, et al
    Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis.
    PLoS One. 2018;13:e0201268.
    PubMed     Text format     Abstract available


  49. MOTOYAMA H, Tamori A, Kubo S, Uchida-Kobayashi S, et al
    Correction: Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
    PLoS One. 2018;13:e0201423.
    PubMed     Text format     Abstract available


  50. EVON DM, Stewart PW, Amador J, Serper M, et al
    A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.
    PLoS One. 2018;13:e0196908.
    PubMed     Text format     Abstract available


  51. NEESGAARD B, Ruhwald M, Krarup HB, Weis N, et al
    Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail.
    PLoS One. 2018;13:e0201629.
    PubMed     Text format     Abstract available


  52. DEMSISS W, Seid A, Fiseha T
    Hepatitis B and C: Seroprevalence, knowledge, practice and associated factors among medicine and health science students in Northeast Ethiopia.
    PLoS One. 2018;13:e0196539.
    PubMed     Text format     Abstract available


  53. PARK H, Jeong D, Nguyen P, Henry L, et al
    Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis.
    PLoS One. 2018;13:e0196452.
    PubMed     Text format     Abstract available


    January 2017
  54. ASSELAH T, Moreno C, Sarrazin C, Gschwantler M, et al
    Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naive Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.
    PLoS One. 2017;12:e0168713.
    PubMed     Text format     Abstract available


  55. ZHU Z, Tran H, Mathahs MM, Moninger TO, et al
    HCV Induces Telomerase Reverse Transcriptase, Increases Its Catalytic Activity, and Promotes Caspase Degradation in Infected Human Hepatocytes.
    PLoS One. 2017;12:e0166853.
    PubMed     Text format     Abstract available


  56. WANG SC, Lai KR, Li CY, Chiang CS, et al
    The Paradoxical Effects of Different Hepatitis C Viral Loads on Host DNA Damage and Repair Abilities.
    PLoS One. 2017;12:e0164281.
    PubMed     Text format     Abstract available


  57. STAHMEYER JT, Rossol S, Liersch S, Guerra I, et al
    Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
    PLoS One. 2017;12:e0169401.
    PubMed     Text format     Abstract available


  58. PUGA MA, Bandeira LM, Pompilio MA, Croda J, et al
    Prevalence and Incidence of HCV Infection among Prisoners in Central Brazil.
    PLoS One. 2017;12:e0169195.
    PubMed     Text format     Abstract available


  59. KIM DY, Han KH, Jun B, Kim TH, et al
    Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.
    PLoS One. 2017;12:e0167770.
    PubMed     Text format     Abstract available


  60. HU J, Gu X, Tao X, Qian Y, et al
    Prevalence and Trends of HIV, Syphilis, and HCV in Migrant and Resident Men Who Have Sex with Men in Shandong, China: Results from a Serial Cross-Sectional Study.
    PLoS One. 2017;12:e0170443.
    PubMed     Text format     Abstract available


  61. DEGRE D, Serste T, Lasser L, Delwaide J, et al
    Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
    PLoS One. 2017;12:e0170933.
    PubMed     Text format     Abstract available


  62. INOUE T, Hmwe SS, Shimada N, Kato K, et al
    Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
    PLoS One. 2017;12:e0170667.
    PubMed     Text format     Abstract available


  63. ZHAI N, Li H, Song H, Yang Y, et al
    Hepatitis C Virus Induces MDSCs-Like Monocytes through TLR2/PI3K/AKT/STAT3 Signaling.
    PLoS One. 2017;12:e0170516.
    PubMed     Text format     Abstract available


  64. GAMBATO M, Caro-Perez N, Gonzalez P, Canete N, et al
    Correction: Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon.
    PLoS One. 2017;12:e0170913.
    PubMed     Text format     Abstract available


  65. TSUTSUMI T, Okushin K, Enooku K, Fujinaga H, et al
    Nonstructural 5A Protein of Hepatitis C Virus Interferes with Toll-Like Receptor Signaling and Suppresses the Interferon Response in Mouse Liver.
    PLoS One. 2017;12:e0170461.
    PubMed     Text format     Abstract available


  66. NIEN HC, Hsu SJ, Su TH, Yang PJ, et al
    High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments.
    PLoS One. 2017;12:e0170028.
    PubMed     Text format     Abstract available


  67. ZHANG C, Hua R, Cui Y, Wang S, et al
    Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearance.
    PLoS One. 2017;12:e0171217.
    PubMed     Text format     Abstract available


  68. WELSCH C, Efinger M, von Wagner M, Herrmann E, et al
    Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response.
    PLoS One. 2017;12:e0171755.
    PubMed     Text format     Abstract available


  69. RUIZ-EXTREMERA A, Pavon-Castillero EJ, Florido M, Munoz de Rueda P, et al
    Influence of HLA class I, HLA class II and KIRs on vertical transmission and chronicity of hepatitis C virus in children.
    PLoS One. 2017;12:e0172527.
    PubMed     Text format     Abstract available


  70. MIYAKI E, Hiraga N, Imamura M, Uchida T, et al
    Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus.
    PLoS One. 2017;12:e0172412.
    PubMed     Text format     Abstract available


  71. KONDILI LA, Gaeta GB, Ieluzzi D, Zignego AL, et al
    Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.
    PLoS One. 2017;12:e0172159.
    PubMed     Text format     Abstract available


  72. LIN SY, Lin CL, Ju SW, Wang IK, et al
    Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study.
    PLoS One. 2017;12:e0173125.
    PubMed     Text format     Abstract available


  73. RALLON N, Garcia M, Garcia-Samaniego J, Rodriguez N, et al
    HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells.
    PLoS One. 2017;12:e0173943.
    PubMed     Text format     Abstract available


  74. GUPTA N, Kabahizi J, Mukabatsinda C, Walker TD, et al
    "Waiting for DAAs": A retrospective chart review of patients with untreated hepatitis C in Rwanda.
    PLoS One. 2017;12:e0174148.
    PubMed     Text format     Abstract available


  75. GUINOISEAU T, Moreau A, Hohnadel G, Ngo-Giang-Huong N, et al
    Deep sequencing is an appropriate tool for the selection of unique Hepatitis C virus (HCV) variants after single genomic amplification.
    PLoS One. 2017;12:e0174852.
    PubMed     Text format     Abstract available


  76. KACZMAREK DJ, Kokordelis P, Kramer B, Glassner A, et al
    Alterations of the NK cell pool in HIV/HCV co-infection.
    PLoS One. 2017;12:e0174465.
    PubMed     Text format     Abstract available


  77. CHEN H, Chen L
    Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China.
    PLoS One. 2017;12:e0175189.
    PubMed     Text format     Abstract available


  78. KOMOLMIT P, Charoensuk K, Thanapirom K, Suksawatamnuay S, et al
    Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial.
    PLoS One. 2017;12:e0174608.
    PubMed     Text format     Abstract available


  79. FERNANDEZ-CABALLERO JA, Alvarez M, Chueca N, Perez AB, et al
    The cobas(R) HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice.
    PLoS One. 2017;12:e0175564.
    PubMed     Text format     Abstract available


  80. YANG CM, Yoon JC, Park JH, Lee JM, et al
    Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3.
    PLoS One. 2017;12:e0175793.
    PubMed     Text format     Abstract available


  81. CHLIBEK R, Smetana J, Sosovickova R, Gal P, et al
    Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening.
    PLoS One. 2017;12:e0175525.
    PubMed     Text format     Abstract available


  82. LE GUILLOU-GUILLEMETTE H, Pivert A, Bouthry E, Henquell C, et al
    Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma.
    PLoS One. 2017;12:e0174651.
    PubMed     Text format     Abstract available


  83. CAPILENO YA, Van den Bergh R, Donchunk D, Hinderaker SG, et al
    Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan.
    PLoS One. 2017;12:e0175562.
    PubMed     Text format     Abstract available


  84. PENE V, Lemasson M, Harper F, Pierron G, et al
    Role of cleavage at the core-E1 junction of hepatitis C virus polyprotein in viral morphogenesis.
    PLoS One. 2017;12:e0175810.
    PubMed     Text format     Abstract available


  85. FRIAS M, Rivero-Juarez A, Tellez F, Perez-Perez M, et al
    Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapy.
    PLoS One. 2017;12:e0177141.
    PubMed     Text format     Abstract available


  86. MOQUEET N, Kanagaratham C, Gill MJ, Hull M, et al
    A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection.
    PLoS One. 2017;12:e0176282.
    PubMed     Text format     Abstract available


  87. BIRGER RB, Le T, Kouyos RD, Grenfell BT, et al
    The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam.
    PLoS One. 2017;12:e0177195.
    PubMed     Text format     Abstract available


  88. CHANG CC, Hsu HJ, Yen JH, Lo SY, et al
    A Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81.
    PLoS One. 2017;12:e0177383.
    PubMed     Text format     Abstract available


  89. WASITTHANKASEM R, Vichaiwattana P, Siripon N, Posuwan N, et al
    Assessment of hepatitis C virus infection in two adjacent Thai provinces with drastically different seroprevalence.
    PLoS One. 2017;12:e0177022.
    PubMed     Text format     Abstract available


  90. D'ARMINIO MONFORTE A, Cozzi-Lepri A, Ceccherini-Silberstein F, De Luca A, et al
    Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.
    PLoS One. 2017;12:e0177402.
    PubMed     Text format     Abstract available


  91. AGGARWAL R, Chen Q, Goel A, Seguy N, et al
    Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.
    PLoS One. 2017;12:e0176503.
    PubMed     Text format     Abstract available


  92. CENTO V, Nguyen THT, Di Carlo D, Biliotti E, et al
    Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.
    PLoS One. 2017;12:e0177352.
    PubMed     Text format     Abstract available


  93. ECKHARDT B, Winkelstein ER, Shu MA, Carden MR, et al
    Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention.
    PLoS One. 2017;12:e0177341.
    PubMed     Text format     Abstract available


  94. HUNDIE GB, Raj VS, GebreMichael D, Pas SD, et al
    Genetic diversity of hepatitis C virus in Ethiopia.
    PLoS One. 2017;12:e0179064.
    PubMed     Text format     Abstract available


  95. NAIK AS, Owsianka A, Palmer BA, O'Halloran CJ, et al
    Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus.
    PLoS One. 2017;12:e0175349.
    PubMed     Text format     Abstract available


  96. EL HADAD S, Al-Hamdan H, Linjawi S
    Partial sequencing analysis of the NS5B region confirmed the predominance of hepatitis C virus genotype 1 infection in Jeddah, Saudi Arabia.
    PLoS One. 2017;12:e0178225.
    PubMed     Text format     Abstract available


  97. ALVARO-MECA A, Berenguer J, Diaz A, Micheloud D, et al
    Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era.
    PLoS One. 2017;12:e0179493.
    PubMed     Text format     Abstract available


  98. CHU PS, Nakamoto N, Taniki N, Ojiro K, et al
    On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C.
    PLoS One. 2017;12:e0179096.
    PubMed     Text format     Abstract available


  99. LEE JW, Kim W, Kwon EK, Kim Y, et al
    Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.
    PLoS One. 2017;12:e0179094.
    PubMed     Text format     Abstract available


  100. CAPILENO YA, Van den Bergh R, Donchuk D, Hinderaker SG, et al
    Correction: Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan.
    PLoS One. 2017;12:e0180286.
    PubMed     Text format     Abstract available


  101. MASCIA C, Vita S, Zuccala P, Marocco R, et al
    Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.
    PLoS One. 2017;12:e0179400.
    PubMed     Text format     Abstract available


  102. ELSHERIF O, Bannan C, Keating S, McKiernan S, et al
    Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response.
    PLoS One. 2017;12:e0178398.
    PubMed     Text format     Abstract available


  103. LIN HC, Xirasagar S, Lee HC, Huang CC, et al
    Association of Alzhemier's disease with hepatitis C among patients with bipolar disorder.
    PLoS One. 2017;12:e0179312.
    PubMed     Text format     Abstract available


  104. ISHIZAKI A, Tran VT, Nguyen CH, Tanimoto T, et al
    Discrepancies in prevalence trends for HIV, hepatitis B virus, and hepatitis C virus in Haiphong, Vietnam from 2007 to 2012.
    PLoS One. 2017;12:e0179616.
    PubMed     Text format     Abstract available


  105. BELAUNZARAN-ZAMUDIO PF, Mosqueda-Gomez JL, Macias-Hernandez A, Sierra-Madero JG, et al
    Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico.
    PLoS One. 2017;12:e0179931.
    PubMed     Text format     Abstract available


  106. SHIU TY, Huang SM, Shih YL, Chu HC, et al
    Correction: Hepatitis C Virus Core Protein Down-Regulates p21Waf1/Cip1 and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells.
    PLoS One. 2017;12:e0181299.
    PubMed     Text format     Abstract available


  107. SNOW KJ, Richards AH, Kinner SA
    Use of multiple data sources to estimate hepatitis C seroprevalence among prisoners: A retrospective cohort study.
    PLoS One. 2017;12:e0180646.
    PubMed     Text format     Abstract available


  108. LEVENTER-ROBERTS M, Hammerman A, Brufman I, Hoshen M, et al
    Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.
    PLoS One. 2017;12:e0176858.
    PubMed     Text format     Abstract available


  109. LOPEZ-RODRIGUEZ R, Hernandez-Bartolome A, Borque MJ, Rodriguez-Munoz Y, et al
    Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C.
    PLoS One. 2017;12:e0180927.
    PubMed     Text format     Abstract available


  110. DALGARD O, Weiland O, Noraberg G, Karlsen L, et al
    Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    PLoS One. 2017;12:e0179764.
    PubMed     Text format     Abstract available


  111. ANDRE-GARNIER E, Besse B, Rodallec A, Ribeyrol O, et al
    An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains.
    PLoS One. 2017;12:e0179562.
    PubMed     Text format     Abstract available


  112. NEUKAM K, Martinez AP, Culasso ACA, Ridruejo E, et al
    NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b.
    PLoS One. 2017;12:e0182193.
    PubMed     Text format     Abstract available


  113. RUSSELLI G, Pizzillo P, Iannolo G, Barbera F, et al
    HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation.
    PLoS One. 2017;12:e0181683.
    PubMed     Text format     Abstract available


  114. SABET S, George MA, El-Shorbagy HM, Bassiony H, et al
    Gelatin nanoparticles enhance delivery of hepatitis C virus recombinant NS2 gene.
    PLoS One. 2017;12:e0181723.
    PubMed     Text format     Abstract available


  115. MERDAN M, Bekiryazici Z, Kesemen T, Khaniyev T, et al
    Deterministic stability and random behavior of a Hepatitis C model.
    PLoS One. 2017;12:e0181571.
    PubMed     Text format     Abstract available


  116. STELZL E, Haas B, Bauer B, Zhang S, et al
    First identification of a recombinant form of hepatitis C virus in Austrian patients by full-genome next generation sequencing.
    PLoS One. 2017;12:e0181273.
    PubMed     Text format     Abstract available


  117. TAN WG, Zubkova I, Kachko A, Wells F, et al
    Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens.
    PLoS One. 2017;12:e0181578.
    PubMed     Text format     Abstract available


  118. HUGHES MG JR, Tucker WW, Reddy S, Brier ME, et al
    Rate of hepatitis C viral clearance by human livers in human patients: Liver transplantation modeling primary infection and implications for studying entry inhibition.
    PLoS One. 2017;12:e0180719.
    PubMed     Text format     Abstract available


  119. SAGNELLI C, Uberti-Foppa C, Hasson H, Bellini G, et al
    Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients.
    PLoS One. 2017;12:e0181890.
    PubMed     Text format     Abstract available


  120. NAGAOKI Y, Imamura M, Aikata H, Daijo K, et al
    The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
    PLoS One. 2017;12:e0182710.
    PubMed     Text format     Abstract available


  121. HUANG CM, Chang KC, Hung CH, Chiu KW, et al
    Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C.
    PLoS One. 2017;12:e0182204.
    PubMed     Text format     Abstract available


  122. DE WEGGHELEIRE A, An S, De Baetselier I, Soeung P, et al
    A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening.
    PLoS One. 2017;12:e0183530.
    PubMed     Text format     Abstract available


  123. BUTT ZA, Shrestha N, Wong S, Kuo M, et al
    A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia.
    PLoS One. 2017;12:e0183609.
    PubMed     Text format     Abstract available


  124. COUTO I, Victoria M, Veloso VG, Rodrigues L, et al
    Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection.
    PLoS One. 2017;12:e0174453.
    PubMed     Text format     Abstract available


  125. CARRIERI MP, Marcellin F, Fressard L, Preau M, et al
    Suicide risk in a representative sample of people receiving HIV care: Time to target most-at-risk populations (ANRS VESPA2 French national survey).
    PLoS One. 2017;12:e0171645.
    PubMed     Text format     Abstract available


  126. MANICKAM C, Wachtman L, Martinot AJ, Giavedoni LD, et al
    Metabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus).
    PLoS One. 2017;12:e0170240.
    PubMed     Text format     Abstract available


  127. SHIER MK, Iles JC, El-Wetidy MS, Ali HH, et al
    Molecular characterization and epidemic history of hepatitis C virus using core sequences of isolates from Central Province, Saudi Arabia.
    PLoS One. 2017;12:e0184163.
    PubMed     Text format     Abstract available


  128. HERMETET C, Dubois F, Gaudy-Graffin C, Bacq Y, et al
    Continuum of hepatitis C care in France: A 20-year cohort study.
    PLoS One. 2017;12:e0183232.
    PubMed     Text format     Abstract available


  129. KJAERGAARD M, Thiele M, Jansen C, Staehr Madsen B, et al
    High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal.
    PLoS One. 2017;12:e0173992.
    PubMed     Text format     Abstract available


  130. ZHENG Z, Sze CW, Keng CT, Al-Haddawi M, et al
    Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model.
    PLoS One. 2017;12:e0184127.
    PubMed     Text format     Abstract available


  131. GOMEZ-MORENO AZ, Pineda-Tenor D, Jimenez-Sousa MA, Sanchez-Ruano JJ, et al
    Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study.
    PLoS One. 2017;12:e0184404.
    PubMed     Text format     Abstract available


  132. VUTIEN P, Jin M, Le MH, Nguyen P, et al
    Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis.
    PLoS One. 2017;12:e0183851.
    PubMed     Text format     Abstract available


  133. CHI X, Zhao X, Wang W, Niu Y, et al
    Fusion expression of Occludin extracellular loops and an alpha-helical bundle: A new research model for tight junction.
    PLoS One. 2017;12:e0175516.
    PubMed     Text format     Abstract available


  134. CHEN HC, Chung CH, Wang CH, Lin JC, et al
    Increased risk of sudden sensorineural hearing loss in patients with hepatitis virus infection.
    PLoS One. 2017;12:e0175266.
    PubMed     Text format     Abstract available


  135. KEATING SM, Dodge JL, Norris PJ, Heitman J, et al
    The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study.
    PLoS One. 2017;12:e0181004.
    PubMed     Text format     Abstract available


  136. NAKAMURA M, Kanda T, Jiang X, Haga Y, et al
    Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis.
    PLoS One. 2017;12:e0177302.
    PubMed     Text format     Abstract available


  137. TUDESQ JJ, Dunyach-Remy C, Combescure C, Doncesco R, et al
    Microbial translocation is correlated with HIV evolution in HIV-HCV co-infected patients.
    PLoS One. 2017;12:e0183372.
    PubMed     Text format     Abstract available


  138. ROSINSKA M, Parda N, Kolakowska A, Godzik P, et al
    Factors associated with hepatitis C prevalence differ by the stage of liver fibrosis: A cross-sectional study in the general population in Poland, 2012-2016.
    PLoS One. 2017;12:e0185055.
    PubMed     Text format     Abstract available


  139. CHIU NC, Su CW, Liu CA, Huang YH, et al
    Interval to vascularization development in cirrhotic precursor nodules in patients with hepatitis B and C virus co-infections.
    PLoS One. 2017;12:e0178841.
    PubMed     Text format     Abstract available


  140. UITTE DE WILLIGE S, Keane FM, Bowen DG, Malfliet JJMC, et al
    Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease.
    PLoS One. 2017;12:e0178987.
    PubMed     Text format     Abstract available


  141. NAGATY A, Abd El-Wahab EW
    Real-life results of sofosbuvir based therapy in chronic hepatitis C -naive and -experienced patients in Egypt.
    PLoS One. 2017;12:e0184654.
    PubMed     Text format     Abstract available


  142. KIM YA, Trinh S, Thura S, Kyi KP, et al
    Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar.
    PLoS One. 2017;12:e0181603.
    PubMed     Text format     Abstract available


  143. BIADGO B, Shiferaw E, Woldu B, Alene KA, et al
    Transfusion-transmissible viral infections among blood donors at the North Gondar district blood bank, northwest Ethiopia: A three year retrospective study.
    PLoS One. 2017;12:e0180416.
    PubMed     Text format     Abstract available


  144. PARASCHIV S, Banica L, Nicolae I, Niculescu I, et al
    Epidemic dispersion of HIV and HCV in a population of co-infected Romanian injecting drug users.
    PLoS One. 2017;12:e0185866.
    PubMed     Text format     Abstract available


  145. GOUVEIA LR, Santos JC, Silva RD, Batista AD, et al
    Diagnosis of coinfection by schistosomiasis and viral hepatitis B or C using 1H NMR-based metabonomics.
    PLoS One. 2017;12:e0182196.
    PubMed     Text format     Abstract available


  146. UEMURA H, Tsukada K, Mizushima D, Aoki T, et al
    Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
    PLoS One. 2017;12:e0186255.
    PubMed     Text format     Abstract available


  147. BURCHILL MA, Roby JA, Crochet N, Wind-Rotolo M, et al
    Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy.
    PLoS One. 2017;12:e0186213.
    PubMed     Text format     Abstract available


  148. RIOUALEN C, Da Costa Q, Chetrit B, Charafe-Jauffret E, et al
    HTS-Net: An integrated regulome-interactome approach for establishing network regulation models in high-throughput screenings.
    PLoS One. 2017;12:e0185400.
    PubMed     Text format     Abstract available


  149. DUFFY D, Mottez E, Ainsworth S, Buivan TP, et al
    An in vitro diagnostic certified point of care single nucleotide test for IL28B polymorphisms.
    PLoS One. 2017;12:e0183084.
    PubMed     Text format     Abstract available


  150. CHEN YI MEI SLG, Thompson AJ, Christensen B, Cunningham G, et al
    Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection.
    PLoS One. 2017;12:e0185609.
    PubMed     Text format     Abstract available


  151. DULTZ G, Graubard BI, Martin P, Welker MW, et al
    Liver transplantation for chronic hepatitis C virus infection in the United States 2002-2014: An analysis of the UNOS/OPTN registry.
    PLoS One. 2017;12:e0186898.
    PubMed     Text format     Abstract available


  152. HARFOUCHE M, Chemaitelly H, Kouyoumjian SP, Mahmud S, et al
    Hepatitis C virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-regressions.
    PLoS One. 2017;12:e0187177.
    PubMed     Text format     Abstract available


  153. ROZERA G, Fabbri G, Lorenzini P, Mastrorosa I, et al
    Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals.
    PLoS One. 2017;12:e0187095.
    PubMed     Text format     Abstract available


  154. MAROT A, Henrion J, Knebel JF, Moreno C, et al
    Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.
    PLoS One. 2017;12:e0186715.
    PubMed     Text format     Abstract available


  155. KONDILI LA, Gaeta GB, Brunetto MR, Di Leo A, et al
    Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.
    PLoS One. 2017;12:e0185728.
    PubMed     Text format     Abstract available


  156. LOGGI E, Galli S, Vitale G, Di Donato R, et al
    Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods.
    PLoS One. 2017;12:e0187755.
    PubMed     Text format     Abstract available


  157. KONERMAN MA, Lu D, Zhang Y, Thomson M, et al
    Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C.
    PLoS One. 2017;12:e0187344.
    PubMed     Text format     Abstract available


  158. SHIMIZU JF, Pereira CM, Bittar C, Batista MN, et al
    Multiple effects of toxins isolated from Crotalus durissus terrificus on the hepatitis C virus life cycle.
    PLoS One. 2017;12:e0187857.
    PubMed     Text format     Abstract available


  159. STROFFOLINI T, Sagnelli E, Andriulli A, Colloredo G, et al
    Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis.
    PLoS One. 2017;12:e0185710.
    PubMed     Text format     Abstract available


  160. GARRIGA C, Manzanares-Laya S, Garcia de Olalla P, Gorrindo P, et al
    Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns.
    PLoS One. 2017;12:e0187893.
    PubMed     Text format     Abstract available


  161. CARLUCCI JG, Farooq SA, Sizemore L, Rickles M, et al
    Low hepatitis C antibody screening rates among an insured population of Tennessean Baby Boomers.
    PLoS One. 2017;12:e0188624.
    PubMed     Text format     Abstract available


  162. BRAGA ACS, Carneiro BM, Batista MN, Akinaga MM, et al
    Heat shock proteins HSPB8 and DNAJC5B have HCV antiviral activity.
    PLoS One. 2017;12:e0188467.
    PubMed     Text format     Abstract available


  163. CANINI L, Imamura M, Kawakami Y, Uprichard SL, et al
    HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.
    PLoS One. 2017;12:e0187409.
    PubMed     Text format     Abstract available


  164. COMSTOCK E, Kim CW, Murphy A, Emmanuel B, et al
    Transcriptional profiling of PBMCs unravels B cell mediated immunopathogenic imprints of HCV vasculitis.
    PLoS One. 2017;12:e0188314.
    PubMed     Text format     Abstract available


  165. LU G, Huang J, Yang Q, Xu H, et al
    Identification and genetic characterization of hepacivirus and pegivirus in commercial equine serum products in China.
    PLoS One. 2017;12:e0189208.
    PubMed     Text format     Abstract available


  166. SMITH JW, Kroker-Lobos MF, Lazo M, Rivera-Andrade A, et al
    Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence.
    PLoS One. 2017;12:e0189255.
    PubMed     Text format     Abstract available


    January 2016
  167. GONZALEZ-ALDACO K, Rebello Pinho JR, Roman S, Gleyzer K, et al
    Association with Spontaneous Hepatitis C Viral Clearance and Genetic Differentiation of IL28B/IFNL4 Haplotypes in Populations from Mexico.
    PLoS One. 2016;11:e0146258.
    PubMed     Text format     Abstract available


  168. HANDISURYA A, Kerscher C, Tura A, Herkner H, et al
    Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients.
    PLoS One. 2016;11:e0145319.
    PubMed     Text format     Abstract available


  169. BRANCHE E, Conzelmann S, Parisot C, Bedert L, et al
    Hepatitis C Virus Increases Occludin Expression via the Upregulation of Adipose Differentiation-Related Protein.
    PLoS One. 2016;11:e0146000.
    PubMed     Text format     Abstract available


  170. ULITZKY L, Lafer MM, KuKuruga MA, Silberstein E, et al
    A New Signaling Pathway for HCV Inhibition by Estrogen: GPR30 Activation Leads to Cleavage of Occludin by MMP-9.
    PLoS One. 2016;11:e0145212.
    PubMed     Text format     Abstract available


  171. CHEN R, Kobewka M, Addison W, Lachance G, et al
    Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice.
    PLoS One. 2016;11:e0147007.
    PubMed     Text format     Abstract available


  172. WEDEMEYER H, Forns X, Hezode C, Lee SS, et al
    Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
    PLoS One. 2016;11:e0145409.
    PubMed     Text format     Abstract available


  173. MOON JS, Lee SH, Kim EJ, Cho H, et al
    Inhibition of Hepatitis C Virus in Mice by a Small Interfering RNA Targeting a Highly Conserved Sequence in Viral IRES Pseudoknot.
    PLoS One. 2016;11:e0146710.
    PubMed     Text format     Abstract available


  174. SINGH S, Vedi S, Samrat SK, Li W, et al
    Heterologous Immunity between Adenoviruses and Hepatitis C Virus: A New Paradigm in HCV Immunity and Vaccines.
    PLoS One. 2016;11:e0146404.
    PubMed     Text format     Abstract available


  175. GUPTA G, Song J
    C-Terminal Auto-Regulatory Motif of Hepatitis C Virus NS5B Interacts with Human VAPB-MSP to Form a Dynamic Replication Complex.
    PLoS One. 2016;11:e0147278.
    PubMed     Text format     Abstract available


  176. ZHAO Q, Wen Y, Jiang Y, Zhang C, et al
    Next Generation Sequencing-Based Investigation of Potential Patient-to-Patient Hepatitis C Virus Transmission during Hemodialytic Treatment.
    PLoS One. 2016;11:e0147566.
    PubMed     Text format     Abstract available


  177. LIU S, Zhao T, Song B, Zhou J, et al
    Comparative Proteomics Reveals Important Viral-Host Interactions in HCV-Infected Human Liver Cells.
    PLoS One. 2016;11:e0147991.
    PubMed     Text format     Abstract available


  178. ALDAMIZ-ECHEVARRIA T, Berenguer J, Miralles P, Jimenez-Sousa MA, et al
    Soluble Adhesion Molecules in Patients Coinfected with HIV and HCV: A Predictor of Outcome.
    PLoS One. 2016;11:e0148537.
    PubMed     Text format     Abstract available


  179. WEI Y, Li J, Qing J, Huang M, et al
    Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking.
    PLoS One. 2016;11:e0148181.
    PubMed     Text format     Abstract available


  180. STINDT S, Cebula P, Albrecht U, Keitel V, et al
    Hepatitis C Virus Activates a Neuregulin-Driven Circuit to Modify Surface Expression of Growth Factor Receptors of the ErbB Family.
    PLoS One. 2016;11:e0148711.
    PubMed     Text format     Abstract available


  181. WASITTHANKASEM R, Posuwan N, Vichaiwattana P, Theamboonlers A, et al
    Decreasing Hepatitis C Virus Infection in Thailand in the Past Decade: Evidence from the 2014 National Survey.
    PLoS One. 2016;11:e0149362.
    PubMed     Text format     Abstract available


  182. IZQUIERDO L, Oliveira C, Fournier C, Descamps V, et al
    Hepatitis C Virus Resistance to Carbohydrate-Binding Agents.
    PLoS One. 2016;11:e0149064.
    PubMed     Text format     Abstract available


  183. ROGAL SS, Arnold RM, Chapko M, Hanusa BV, et al
    The Patient-Provider Relationship Is Associated with Hepatitis C Treatment Eligibility: A Prospective Mixed-Methods Cohort Study.
    PLoS One. 2016;11:e0148596.
    PubMed     Text format     Abstract available


  184. CHAABNA K, Kouyoumjian SP, Abu-Raddad LJ
    Hepatitis C Virus Epidemiology in Djibouti, Somalia, Sudan, and Yemen: Systematic Review and Meta-Analysis.
    PLoS One. 2016;11:e0149966.
    PubMed     Text format     Abstract available


  185. CARABALLO CORTES K, Zagordi O, Jablonska J, Pawelczyk A, et al
    Spouse-to-Spouse Transmission and Evolution of Hypervariable Region 1 and 5' Untranslated Region of Hepatitis C Virus Analyzed by Next-Generation Sequencing.
    PLoS One. 2016;11:e0150311.
    PubMed     Text format     Abstract available


  186. WANG C, Shi CX, Rou K, Zhao Y, et al
    Baseline HCV Antibody Prevalence and Risk Factors among Drug Users in China's National Methadone Maintenance Treatment Program.
    PLoS One. 2016;11:e0147922.
    PubMed     Text format     Abstract available


  187. WU CK, Chang KC, Tseng PL, Lu SN, et al
    Comparison of Therapeutic Response and Clinical Outcome between HCV Patients with Normal and Abnormal Alanine Transaminase Levels.
    PLoS One. 2016;11:e0142378.
    PubMed     Text format     Abstract available


  188. O'CONNELL S, Lillis D, Cotter A, O'Dea S, et al
    Opt-Out Panel Testing for HIV, Hepatitis B and Hepatitis C in an Urban Emergency Department: A Pilot Study.
    PLoS One. 2016;11:e0150546.
    PubMed     Text format     Abstract available


  189. BEAUMONT E, Roch E, Chopin L, Roingeard P, et al
    Hepatitis C Virus E1 and E2 Proteins Used as Separate Immunogens Induce Neutralizing Antibodies with Additive Properties.
    PLoS One. 2016;11:e0151626.
    PubMed     Text format     Abstract available


  190. JANJUA NZ, Kuo M, Chong M, Yu A, et al
    Assessing Hepatitis C Burden and Treatment Effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): Design and Characteristics of Linked and Unlinked Participants.
    PLoS One. 2016;11:e0150176.
    PubMed     Text format     Abstract available


  191. YAO M, Lu X, Lei Y, Yang J, et al
    Conditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A Protease Activity.
    PLoS One. 2016;11:e0150894.
    PubMed     Text format     Abstract available


  192. SPINDELBOECK W, Horvath A, Tawdrous M, Schmerbock B, et al
    Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes.
    PLoS One. 2016;11:e0150299.
    PubMed     Text format     Abstract available


  193. ASSELAH T, Thompson AJ, Flisiak R, Romero-Gomez M, et al
    A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.
    PLoS One. 2016;11:e0150569.
    PubMed     Text format     Abstract available


  194. MATSUMOTO N, Ikeda H, Shigefuku R, Hattori N, et al
    Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b.
    PLoS One. 2016;11:e0151238.
    PubMed     Text format     Abstract available


  195. TAWARA S, Tatsumi T, Iio S, Kobayashi I, et al
    Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C.
    PLoS One. 2016;11:e0151828.
    PubMed     Text format     Abstract available


  196. BAGHERI AMIRI F, Mostafavi E, Mirzazadeh A
    HIV, HBV and HCV Coinfection Prevalence in Iran - A Systematic Review and Meta-Analysis.
    PLoS One. 2016;11:e0151946.
    PubMed     Text format     Abstract available


  197. YU JS, Chen WC, Tseng CK, Lin CK, et al
    Sulforaphane Suppresses Hepatitis C Virus Replication by Up-Regulating Heme Oxygenase-1 Expression through PI3K/Nrf2 Pathway.
    PLoS One. 2016;11:e0152236.
    PubMed     Text format     Abstract available


  198. FOSTER GR, Coppola C, Derbala M, Ferenci P, et al
    Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.
    PLoS One. 2016;11:e0151703.
    PubMed     Text format     Abstract available


  199. SAID EA, Al-Reesi I, Al-Riyami M, Al-Naamani K, et al
    A Potential Inhibitory Profile of Liver CD68+ Cells during HCV Infection as Observed by an Increased CD80 and PD-L1 but Not CD86 Expression.
    PLoS One. 2016;11:e0153191.
    PubMed     Text format     Abstract available


  200. RIZK HH, Hamdy NM, Al-Ansari NL, El-Mesallamy HO, et al
    Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4.
    PLoS One. 2016;11:e0153895.
    PubMed     Text format     Abstract available


  201. RAJHI M, Ghedira K, Chouikha A, Djebbi A, et al
    Phylogenetic Analysis and Epidemic History of Hepatitis C Virus Genotype 2 in Tunisia, North Africa.
    PLoS One. 2016;11:e0153761.
    PubMed     Text format     Abstract available


  202. CHUECA N, Rivadulla I, Lovatti R, Reina G, et al
    Using NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms.
    PLoS One. 2016;11:e0153754.
    PubMed     Text format     Abstract available


  203. MACPARLAND SA, Fadel SM, Mihajlovic V, Fawaz A, et al
    HCV Specific IL-21 Producing T Cells but Not IL-17A Producing T Cells Are Associated with HCV Viral Control in HIV/HCV Coinfection.
    PLoS One. 2016;11:e0154433.
    PubMed     Text format     Abstract available


  204. GAO Y, Ren H, Meng F, Li J, et al
    Pathological Roles of Interleukin-22 in the Development of Recurrent Hepatitis C after Liver Transplantation.
    PLoS One. 2016;11:e0154419.
    PubMed     Text format     Abstract available


  205. RAMANATHAN A, Gusarova V, Stahl N, Gurnett-Bander A, et al
    Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
    PLoS One. 2016;11:e0154498.
    PubMed     Text format     Abstract available


  206. HAN Y, Niu J, Wang D, Li Y, et al
    Hepatitis C Virus Protein Interaction Network Analysis Based on Hepatocellular Carcinoma.
    PLoS One. 2016;11:e0153882.
    PubMed     Text format     Abstract available


  207. GALLAY PA, Chatterji U, Bobardt MD, Long Z, et al
    Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175.
    PLoS One. 2016;11:e0152036.
    PubMed     Text format     Abstract available


  208. NGUYEN TRUONG T, Laureillard D, Lacombe K, Duong Thi H, et al
    High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262).
    PLoS One. 2016;11:e0153744.
    PubMed     Text format     Abstract available


  209. IBRAHIM MK, Salum GM, Bader El Din NG, Dawood RM, et al
    Transcriptional Dysregulation of Upstream Signaling of IFN Pathway in Chronic HCV Type 4 Induced Liver Fibrosis.
    PLoS One. 2016;11:e0154512.
    PubMed     Text format     Abstract available


  210. WALDENSTROM J, Westin J, Nystrom K, Christensen P, et al
    Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection.
    PLoS One. 2016;11:e0155142.
    PubMed     Text format     Abstract available


  211. GRANADOS-GARCIA V, Contreras AM, Garcia-Pena C, Salinas-Escudero G, et al
    Cost-Effectiveness Analysis of Different Testing Strategies that Use Antibody Levels to Detect Chronic Hepatitis C in Blood Donors.
    PLoS One. 2016;11:e0154625.
    PubMed     Text format     Abstract available


  212. EMBADE N, Marino Z, Diercks T, Cano A, et al
    Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy.
    PLoS One. 2016;11:e0155094.
    PubMed     Text format     Abstract available


  213. KALAGHATGI P, Sikorski AM, Knops E, Rupp D, et al
    Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents.
    PLoS One. 2016;11:e0155869.
    PubMed     Text format     Abstract available


  214. NEUKAM K, Espinosa N, Collado A, Delgado-Fernandez M, et al
    Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study.
    PLoS One. 2016;11:e0155842.
    PubMed     Text format     Abstract available


  215. WASITTHANKASEM R, Posuwan N, Vichaiwattana P, Theamboonlers A, et al
    Correction: Decreasing Hepatitis C Virus Infection in Thailand in the Past Decade: Evidence from the 2014 National Survey.
    PLoS One. 2016;11:e0152451.
    PubMed     Text format     Abstract available


  216. BERTISCH B, Giudici F, Negro F, Moradpour D, et al
    Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations.
    PLoS One. 2016;11:e0155464.
    PubMed     Text format     Abstract available


  217. STONE J, Martin NK, Hickman M, Hellard M, et al
    The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
    PLoS One. 2016;11:e0156213.
    PubMed     Text format     Abstract available


  218. AMORAS EDA S, Gomes ST, Freitas FB, Santana BB, et al
    Intrahepatic mRNA Expression of FAS, FASL, and FOXP3 Genes Is Associated with the Pathophysiology of Chronic HCV Infection.
    PLoS One. 2016;11:e0156604.
    PubMed     Text format     Abstract available


  219. DIETZ J, Rupp D, Susser S, Vermehren J, et al
    Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy.
    PLoS One. 2016;11:e0156731.
    PubMed     Text format     Abstract available


  220. SILBERSTEIN E, Ulitzky L, Lima LA, Cehan N, et al
    HCV-Mediated Apoptosis of Hepatocytes in Culture and Viral Pathogenesis.
    PLoS One. 2016;11:e0155708.
    PubMed     Text format     Abstract available


  221. NARAYANAN S, Nieh AH, Kenwood BM, Davis CA, et al
    Distinct Roles for Intracellular and Extracellular Lipids in Hepatitis C Virus Infection.
    PLoS One. 2016;11:e0156996.
    PubMed     Text format     Abstract available


  222. CHEN GF, Wei L, Chen J, Duan ZP, et al
    Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.
    PLoS One. 2016;11:e0155934.
    PubMed     Text format     Abstract available


  223. CHIU KW, Nakano T, Chen KD, Lin CC, et al
    Association of IL28B SNPs rs12979860 and rs8099917 on Hepatitis C Virus-RNA Status in Donors/Recipients of Living Donor Liver Transplantation.
    PLoS One. 2016;11:e0156846.
    PubMed     Text format     Abstract available


  224. CANIONI D, Michot JM, Rabiega P, Molina TJ, et al
    In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas.
    PLoS One. 2016;11:e0156384.
    PubMed     Text format     Abstract available


  225. VERNAZ N, Girardin F, Goossens N, Brugger U, et al
    Drug Pricing Evolution in Hepatitis C.
    PLoS One. 2016;11:e0157098.
    PubMed     Text format     Abstract available


  226. HUIK K, Avi R, Pauskar M, Kallas E, et al
    A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs.
    PLoS One. 2016;11:e0156850.
    PubMed     Text format     Abstract available


  227. D'AMBROSIO R, Degasperi E, Aghemo A, Fraquelli M, et al
    Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.
    PLoS One. 2016;11:e0155967.
    PubMed     Text format     Abstract available


  228. ROUX P, Rojas Castro D, Ndiaye K, Debrus M, et al
    Increased Uptake of HCV Testing through a Community-Based Educational Intervention in Difficult-to-Reach People Who Inject Drugs: Results from the ANRS-AERLI Study.
    PLoS One. 2016;11:e0157062.
    PubMed     Text format     Abstract available


  229. BURKE SCHINKEL SC, Carrasco-Medina L, Cooper CL, Crawley AM, et al
    Generalized Liver- and Blood-Derived CD8+ T-Cell Impairment in Response to Cytokines in Chronic Hepatitis C Virus Infection.
    PLoS One. 2016;11:e0157055.
    PubMed     Text format     Abstract available


  230. DOYLE JS, Grebely J, Spelman T, Alavi M, et al
    Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort.
    PLoS One. 2016;11:e0150655.
    PubMed     Text format     Abstract available


  231. ZHOU K, Liang Z, Wang C, Hu F, et al
    Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naive HIV/HCV Co-Infected Patients in China.
    PLoS One. 2016;11:e0157438.
    PubMed     Text format     Abstract available


  232. KUNTZEN T, Kuhn S, Kuntzen D, Seifert B, et al
    Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection.
    PLoS One. 2016;11:e0158512.
    PubMed     Text format     Abstract available


  233. SHI L, Qin E, Zhou J, Zhao J, et al
    HIV and HCV Co-Culture Promotes Profibrogenic Gene Expression through an Epimorphin-Mediated ERK Signaling Pathway in Hepatic Stellate Cells.
    PLoS One. 2016;11:e0158386.
    PubMed     Text format     Abstract available


  234. MLUNDE LB, Sunguya BF, Mbwambo JK, Ubuguyu OS, et al
    A Mismatch between High-Risk Behaviors and Screening of Infectious Diseases among People Who Inject Drugs in Dar es Salaam, Tanzania.
    PLoS One. 2016;11:e0148598.
    PubMed     Text format     Abstract available


  235. MAOR Y, Malnick SD, Melzer E, Leshno M, et al
    Treatment of Chronic Hepatitis C in the Aged - Does It Impact Life Expectancy? A Decision Analysis.
    PLoS One. 2016;11:e0157832.
    PubMed     Text format     Abstract available


  236. PARK SB, Seronello S, Mayer W, Ojcius DM, et al
    Hepatitis C Virus Frameshift/Alternate Reading Frame Protein Suppresses Interferon Responses Mediated by Pattern Recognition Receptor Retinoic-Acid-Inducible Gene-I.
    PLoS One. 2016;11:e0158419.
    PubMed     Text format     Abstract available


  237. ASSELAH T, Moreno C, Sarrazin C, Gschwantler M, et al
    An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naive Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).
    PLoS One. 2016;11:e0158526.
    PubMed     Text format     Abstract available


  238. SPAAN M, Hullegie SJ, Beudeker BJ, Kreefft K, et al
    Frequencies of Circulating MAIT Cells Are Diminished in Chronic HCV, HIV and HCV/HIV Co-Infection and Do Not Recover during Therapy.
    PLoS One. 2016;11:e0159243.
    PubMed     Text format     Abstract available


  239. LIN MV, Sise ME, Pavlakis M, Amundsen BM, et al
    Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    PLoS One. 2016;11:e0158431.
    PubMed     Text format     Abstract available


  240. NEUKAM K, Mira JA, Collado A, Rivero-Juarez A, et al
    Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort.
    PLoS One. 2016;11:e0148104.
    PubMed     Text format     Abstract available


  241. CONRAD KD, Giering F, Erfurth C, Neumann A, et al
    Correction: microRNA-122 Dependent Binding of Ago2 Protein to Hepatitis C Virus RNA Is Associated with Enhanced RNA Stability and Translation Stimulation.
    PLoS One. 2016;11:e0160132.
    PubMed     Text format     Abstract available


  242. STAHMEYER JT, Rossol S, Bert F, Boker KH, et al
    Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.
    PLoS One. 2016;11:e0159976.
    PubMed     Text format     Abstract available


  243. IWASA S, Sato N, Wang CW, Cheng YH, et al
    The Phospholipid:Diacylglycerol Acyltransferase Lro1 Is Responsible for Hepatitis C Virus Core-Induced Lipid Droplet Formation in a Yeast Model System.
    PLoS One. 2016;11:e0159324.
    PubMed     Text format     Abstract available


  244. ZHANG YH, Zhao Y, Rajapaksa US, Lawrence TM, et al
    A Comprehensive Analysis of the Impact of HIV on HCV Immune Responses and Its Association with Liver Disease Progression in a Unique Plasma Donor Cohort.
    PLoS One. 2016;11:e0158037.
    PubMed     Text format     Abstract available


  245. CHATTERJI U, Bobardt M, Schaffer L, Wood M, et al
    Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection.
    PLoS One. 2016;11:e0159511.
    PubMed     Text format     Abstract available


  246. CHEKURI S, Nickerson J, Bichoupan K, Sefcik R, et al
    Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus.
    PLoS One. 2016;11:e0159413.
    PubMed     Text format     Abstract available


  247. ELHEFNAWI M, Kim T, Kamar MA, Min S, et al
    In Silico Design and Experimental Validation of siRNAs Targeting Conserved Regions of Multiple Hepatitis C Virus Genotypes.
    PLoS One. 2016;11:e0159211.
    PubMed     Text format     Abstract available


  248. CHEN M, Wong WW, Law MG, Kiertiburanakul S, et al
    Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival.
    PLoS One. 2016;11:e0150512.
    PubMed     Text format     Abstract available


  249. SOLOMON SS, Srikrishnan AK, McFall AM, Kumar MS, et al
    Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, India.
    PLoS One. 2016;11:e0147879.
    PubMed     Text format     Abstract available


  250. BOURGI K, Brar I, Baker-Genaw K
    Health Disparities in Hepatitis C Screening and Linkage to Care at an Integrated Health System in Southeast Michigan.
    PLoS One. 2016;11:e0161241.
    PubMed     Text format     Abstract available


  251. CHEN HJ, Huang N, Chen LS, Chou YJ, et al
    Does Pay-For-Performance Program Increase Providers Adherence to Guidelines for Managing Hepatitis B and Hepatitis C Virus Infection in Taiwan?
    PLoS One. 2016;11:e0161002.
    PubMed     Text format     Abstract available


  252. HSIAO PJ, Hsieh PF, Chou EC, Lai HC, et al
    Anti-Viral Therapy and Decreased Sexual Desire in Patients with Chronic Hepatitis C.
    PLoS One. 2016;11:e0160450.
    PubMed     Text format     Abstract available


  253. KLIEMANN DA, Tovo CV, Gorini da Veiga AB, Machado AL, et al
    Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank.
    PLoS One. 2016;11:e0159924.
    PubMed     Text format     Abstract available


  254. BERGER KL, Sarrazin C, Nelson DR, Scherer J, et al
    Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
    PLoS One. 2016;11:e0160668.
    PubMed     Text format     Abstract available


  255. BAIOCCHINI A, Montaldo C, Conigliaro A, Grimaldi A, et al
    Extracellular Matrix Molecular Remodeling in Human Liver Fibrosis Evolution.
    PLoS One. 2016;11:e0151736.
    PubMed     Text format     Abstract available


  256. GARBUGLIA AR, Visco-Comandini U, Lionetti R, Lapa D, et al
    Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors.
    PLoS One. 2016;11:e0158989.
    PubMed     Text format     Abstract available


  257. BRADSHAW D, Raghwani J, Jacka B, Sacks-Davis R, et al
    Venue-Based Networks May Underpin HCV Transmissions amongst HIV-Infected Gay and Bisexual Men.
    PLoS One. 2016;11:e0162002.
    PubMed     Text format     Abstract available


  258. KRAMER B, Finnemann C, Sastre B, Lutz P, et al
    IL-28B Genetic Variants Determine the Extent of Monocyte-Induced Activation of NK Cells in Hepatitis C.
    PLoS One. 2016;11:e0162068.
    PubMed     Text format     Abstract available


  259. ARAUJO OC, Rosa AS, Fernandes A, Niel C, et al
    RASSF1A and DOK1 Promoter Methylation Levels in Hepatocellular Carcinoma, Cirrhotic and Non-Cirrhotic Liver, and Correlation with Liver Cancer in Brazilian Patients.
    PLoS One. 2016;11:e0153796.
    PubMed     Text format     Abstract available


  260. CHEN W, Liao B, Hu F, Nie J, et al
    Changing Epidemiology of Hepatitis C Virus Genotype among Patients with Human Immunodeficiency Virus/Hepatitis C Virus Co-Infection in China.
    PLoS One. 2016;11:e0161844.
    PubMed     Text format     Abstract available


  261. BERDEN FA, de Knegt RJ, Blokzijl H, Kuiken SD, et al
    Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study.
    PLoS One. 2016;11:e0161821.
    PubMed     Text format     Abstract available


  262. POOVORAWAN K, Pan-Ngum W, White LJ, Soonthornworasiri N, et al
    Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era.
    PLoS One. 2016;11:e0163095.
    PubMed     Text format     Abstract available


  263. SAMIMI-RAD K, Rahimnia R, Sadeghi M, Malekpour SA, et al
    Epidemic History of Hepatitis C Virus among Patients with Inherited Bleeding Disorders in Iran.
    PLoS One. 2016;11:e0162492.
    PubMed     Text format     Abstract available


  264. WAN Z, Chen Q, Chen X, Duo L, et al
    HCV Diversity among Chinese and Burmese IDUs in Dehong, Yunnan, China.
    PLoS One. 2016;11:e0163062.
    PubMed     Text format     Abstract available


  265. JIMENEZ-SOUSA MA, Gutierrez-Rivas M, Alvaro-Meca A, Garcia-Alvarez M, et al
    NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain.
    PLoS One. 2016;11:e0163197.
    PubMed     Text format     Abstract available


  266. IDE T, Eguchi Y, Harada M, Ishii K, et al
    Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1.
    PLoS One. 2016;11:e0163884.
    PubMed     Text format     Abstract available


  267. HASHIMOTO S, Yatsuhashi H, Abiru S, Yamasaki K, et al
    Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment.
    PLoS One. 2016;11:e0163644.
    PubMed     Text format     Abstract available


  268. NGUYEN LT, Gray E, O'Leary A, Carr M, et al
    The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors.
    PLoS One. 2016;11:e0163900.
    PubMed     Text format     Abstract available


  269. VAN SANTEN DK, de Vos AS, Matser A, Willemse SB, et al
    Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands.
    PLoS One. 2016;11:e0163488.
    PubMed     Text format     Abstract available


  270. MATSUNAMI K, Nishida N, Kaneko N, Ikeo K, et al
    Genome-Wide Association Study Identifies ZNF354C Variants Associated with Depression from Interferon-Based Therapy for Chronic Hepatitis C.
    PLoS One. 2016;11:e0164418.
    PubMed     Text format     Abstract available


  271. COLLI A, Fraquelli M, Prati D, Riva A, et al
    Deciding on Interferon-Free Treatment for Chronic Hepatitis C: Updating Liver Stiffness Cut-Off Values to Maximize Benefit.
    PLoS One. 2016;11:e0164452.
    PubMed     Text format     Abstract available


  272. GHORI NU, Shafique A, Hayat MQ, Anjum S, et al
    The Phylogeographic and Spatiotemporal Spread of HCV in Pakistani Population.
    PLoS One. 2016;11:e0164265.
    PubMed     Text format     Abstract available


  273. WHITE DA, Anderson ES, Pfeil SK, Deering LJ, et al
    Hepatitis C Virus Screening and Emergency Department Length of Stay.
    PLoS One. 2016;11:e0164831.
    PubMed     Text format     Abstract available


  274. DE AVILA AI, Gallego I, Soria ME, Gregori J, et al
    Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir.
    PLoS One. 2016;11:e0164691.
    PubMed     Text format     Abstract available


  275. ALRIC L, Besson C, Lapidus N, Jeannel J, et al
    Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study.
    PLoS One. 2016;11:e0162965.
    PubMed     Text format     Abstract available


  276. FLISIAK R, Shiffman M, Arenas J, Cheinquer H, et al
    A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
    PLoS One. 2016;11:e0164563.
    PubMed     Text format     Abstract available


  277. DAVITKOV P, Chandar AK, Hirsch A, Compan A, et al
    Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C.
    PLoS One. 2016;11:e0163945.
    PubMed     Text format     Abstract available


  278. CHOI YH, Jin N, Kelly F, Sakthivel SK, et al
    Elevation of Alanine Aminotransferase Activity Occurs after Activation of the Cell-Death Signaling Initiated by Pattern-Recognition Receptors but before Activation of Cytolytic Effectors in NK or CD8+ T Cells in the Liver During Acute HCV Infection.
    PLoS One. 2016;11:e0165533.
    PubMed     Text format     Abstract available


  279. SIRAVENHA LG, Siravenha LQ, Madeira LD, Oliveira-Filho AB, et al
    Detection of HCV Persistent Infections in the Dental Pulp: A Novel Approach for the Detection of Past and Ancient Infections.
    PLoS One. 2016;11:e0165272.
    PubMed     Text format     Abstract available


  280. ITAKURA J, Kurosaki M, Hasebe C, Osaki Y, et al
    Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure.
    PLoS One. 2016;11:e0165339.
    PubMed     Text format     Abstract available


  281. MERAT SJ, Molenkamp R, Wagner K, Koekkoek SM, et al
    Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance.
    PLoS One. 2016;11:e0165047.
    PubMed     Text format     Abstract available


  282. ZHANG Y, Cao Y, Zhang R, Zhang X, et al
    Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
    PLoS One. 2016;11:e0165658.
    PubMed     Text format     Abstract available


  283. LOFTFIELD E, O'Brien TR, Pfeiffer RM, Howell CD, et al
    Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials.
    PLoS One. 2016;11:e0166036.
    PubMed     Text format     Abstract available


  284. SU FH, Wu CS, Sung FC, Chang SN, et al
    Correction: Chronic Hepatitis C Virus Infection Is Associated with the Development of Rheumatoid Arthritis: A Nationwide Population-Based Study in Taiwan.
    PLoS One. 2016;11:e0166508.
    PubMed     Text format     Abstract available


  285. MIDGARD H, Bramness JG, Skurtveit S, Haukeland JW, et al
    Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.
    PLoS One. 2016;11:e0166451.
    PubMed     Text format     Abstract available


  286. PALMER BA, Fanning LJ
    Synonymous Co-Variation across the E1/E2 Gene Junction of Hepatitis C Virus Defines Virion Fitness.
    PLoS One. 2016;11:e0167089.
    PubMed     Text format     Abstract available


  287. LEE KY, Chen YH, Hsu SC, Yu MJ, et al
    Phosphorylation of Serine 235 of the Hepatitis C Virus Non-Structural Protein NS5A by Multiple Kinases.
    PLoS One. 2016;11:e0166763.
    PubMed     Text format     Abstract available


  288. AIKEN T, Garber A, Thomas D, Hamon N, et al
    Donor IFNL4 Genotype Is Associated with Early Post-Transplant Fibrosis in Recipients with Hepatitis C.
    PLoS One. 2016;11:e0166998.
    PubMed     Text format     Abstract available


  289. CHANG ML, Kuo CJ, Huang HC, Chu YY, et al
    Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity.
    PLoS One. 2016;11:e0166712.
    PubMed     Text format     Abstract available


  290. GAMBATO M, Caro-Perez N, Gonzalez P, Canete N, et al
    Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon.
    PLoS One. 2016;11:e0166631.
    PubMed     Text format     Abstract available


  291. HAMAD HA, Thurston J, Teague T, Ackad E, et al
    The NS4A Cofactor Dependent Enhancement of HCV NS3 Protease Activity Correlates with a 4D Geometrical Measure of the Catalytic Triad Region.
    PLoS One. 2016;11:e0168002.
    PubMed     Text format     Abstract available


  292. PUIGVEHI M, Hernandez J, Broquetas T, Coll S, et al
    Diagnostic Accuracy of the Enhanced Liver Fibrosis (ELF(R)) Score Using HCV-Infected Serum Samples Cryopreserved for up to 25 Years.
    PLoS One. 2016;11:e0164883.
    PubMed     Text format     Abstract available


  293. NUNEZ-TORRES R, Macias J, Mancebo M, Frias M, et al
    The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients.
    PLoS One. 2016;11:e0168265.
    PubMed     Text format     Abstract available


  294. SARRAZIN C, Manns M, Calleja JL, Garcia-Samaniego J, et al
    HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.
    PLoS One. 2016;11:e0168544.
    PubMed     Text format     Abstract available


  295. EL-GHITANY EM, Farghaly AG, Farag S, Abd El-Wahab EW, et al
    Validation of EGCRISC for Chronic Hepatitis C Infection Screening and Risk Assessment in the Egyptian Population.
    PLoS One. 2016;11:e0168649.
    PubMed     Text format     Abstract available


  296. VILLANI R, Facciorusso A, Bellanti F, Tamborra R, et al
    DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment.
    PLoS One. 2016;11:e0167934.
    PubMed     Text format     Abstract available


  297. YASUI Y, Abe T, Kurosaki M, Higuchi M, et al
    Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma.
    PLoS One. 2016;11:e0154558.
    PubMed     Text format     Abstract available


  298. BOCHAROV G, Meyerhans A, Bessonov N, Trofimchuk S, et al
    Spatiotemporal Dynamics of Virus Infection Spreading in Tissues.
    PLoS One. 2016;11:e0168576.
    PubMed     Text format     Abstract available


  299. DE MIGUEL-DIEZ J, Lopez-de-Andres A, Jimenez-Garcia R, Puente-Maestu L, et al
    Trends in Epidemiology of COPD in HIV-Infected Patients in Spain (1997-2012).
    PLoS One. 2016;11:e0166421.
    PubMed     Text format     Abstract available


  300. NJOKU OS, Manak MM, O'Connell RJ, Shutt AL, et al
    An Evaluation of Selected Populations for HIV-1 Vaccine Cohort Development in Nigeria.
    PLoS One. 2016;11:e0166711.
    PubMed     Text format     Abstract available


  301. LIMA K, de Souza Leal E, Cavalcanti AM, Salustiano DM, et al
    Epidemiological, Clinical and Antiretroviral Susceptibility Characterization of Human Immunodeficiency Virus Subtypes B and Non-B in Pernambuco, Northeast Brazil.
    PLoS One. 2016;11:e0155854.
    PubMed     Text format     Abstract available


  302. FARSHADPOUR F, Taherkhani R, Tajbakhsh S, Gholizadeh Tangestani M, et al
    Prevalence and Trends of Transfusion-Transmissible Viral Infections among Blood Donors in South of Iran: An Eleven-Year Retrospective Study.
    PLoS One. 2016;11:e0157615.
    PubMed     Text format     Abstract available


  303. KIM YI, Kim HS, Park JW
    Higher Ratio of Serum Alpha-Fetoprotein Could Predict Outcomes in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma and Normal Alanine Aminotransferase.
    PLoS One. 2016;11:e0157299.
    PubMed     Text format     Abstract available


  304. YEH CC, Wang WC, Wu CS, Sung FC, et al
    Association of Sjogrens Syndrome in Patients with Chronic Hepatitis Virus Infection: A Population-Based Analysis.
    PLoS One. 2016;11:e0161958.
    PubMed     Text format     Abstract available


  305. REMIS RS, Liu J, Loutfy MR, Tharao W, et al
    Prevalence of Sexually Transmitted Viral and Bacterial Infections in HIV-Positive and HIV-Negative Men Who Have Sex with Men in Toronto.
    PLoS One. 2016;11:e0158090.
    PubMed     Text format     Abstract available


  306. PIEPENBRINK MS, Samuel M, Zheng B, Carter B, et al
    Humoral Dysregulation Associated with Increased Systemic Inflammation among Injection Heroin Users.
    PLoS One. 2016;11:e0158641.
    PubMed     Text format     Abstract available


    January 2015
  307. PFEIL AM, Reich O, Guerra IM, Cure S, et al
    Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C.
    PLoS One. 2015;10:e0126984.
    PubMed     Text format     Abstract available


  308. KUO YH, Chen PF, Wang JH, Chang KC, et al
    Comparison Stratagems of Post-Screening Management of Anti-HCV-Positive Community Residents: Simple Notification, Active Referral, or Accessible Medical Care.
    PLoS One. 2015;10:e0126031.
    PubMed     Text format     Abstract available


  309. ALHAMMAD YM, Maharajh S, Butcher R, Eden JS, et al
    Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection.
    PLoS One. 2015;10:e0126397.
    PubMed     Text format     Abstract available


  310. CHU PS, Ebinuma H, Nakamoto N, Sugiyama K, et al
    Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/ Ribavirin Therapy in Chronic Hepatitis C.
    PLoS One. 2015;10:e0125664.
    PubMed     Text format     Abstract available


  311. RAJALAKSHMY AR, Malathi J, Madhavan HN
    Hepatitis C Virus NS3 Mediated Microglial Inflammation via TLR2/TLR6 MyD88/NF-kappaB Pathway and Toll Like Receptor Ligand Treatment Furnished Immune Tolerance.
    PLoS One. 2015;10:e0125419.
    PubMed     Text format     Abstract available


  312. WASITTHANKASEM R, Vongpunsawad S, Siripon N, Suya C, et al
    Genotypic distribution of hepatitis C virus in Thailand and southeast Asia.
    PLoS One. 2015;10:e0126764.
    PubMed     Text format     Abstract available


  313. BROUARD C, Le Strat Y, Larsen C, Jauffret-Roustide M, et al
    The undiagnosed chronically-infected HCV population in france. Implications for expanded testing recommendations in 2014.
    PLoS One. 2015;10:e0126920.
    PubMed     Text format     Abstract available


  314. KURT R, Chandra PK, Aboulnasr F, Panigrahi R, et al
    Chaperone-Mediated Autophagy Targets IFNAR1 for Lysosomal Degradation in Free Fatty Acid Treated HCV Cell Culture.
    PLoS One. 2015;10:e0125962.
    PubMed     Text format     Abstract available


  315. DE RE V, Caggiari L, De Zorzi M, Repetto O, et al
    Correction: Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases.
    PLoS One. 2015;10:e0128849.
    PubMed     Text format     Abstract available


  316. MCDONALD SA, Dahlui M, Mohamed R, Naning H, et al
    Projections of the Current and Future Disease Burden of Hepatitis C Virus Infection in Malaysia.
    PLoS One. 2015;10:e0128091.
    PubMed     Text format     Abstract available


  317. MUTSO M, Nikonov A, Pihlak A, Zusinaite E, et al
    RNA Interference-Guided Targeting of Hepatitis C Virus Replication with Antisense Locked Nucleic Acid-Based Oligonucleotides Containing 8-oxo-dG Modifications.
    PLoS One. 2015;10:e0128686.
    PubMed     Text format     Abstract available


  318. MATHEW S, Fatima K, Fatmi MQ, Archunan G, et al
    Computational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds.
    PLoS One. 2015;10:e0126510.
    PubMed     Text format     Abstract available


  319. BANSAL R, Frelin L, Brenndorfer ED, Storm G, et al
    Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In Vivo.
    PLoS One. 2015;10:e0128466.
    PubMed     Text format     Abstract available


  320. ROLLET-KURHAJEC KC, Moodie EE, Walmsley S, Cooper C, et al
    Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection - The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index.
    PLoS One. 2015;10:e0129868.
    PubMed     Text format     Abstract available


  321. YOSHIMI S, Ochi H, Murakami E, Uchida T, et al
    Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay.
    PLoS One. 2015;10:e0130022.
    PubMed     Text format     Abstract available


  322. CHEN F, Sun D, Guo Y, Guo W, et al
    Spatiotemporal Scan and Age-Period-Cohort Analysis of Hepatitis C Virus in Henan, China: 2005-2012.
    PLoS One. 2015;10:e0129746.
    PubMed     Text format     Abstract available


  323. SASAKI R, Yamasaki K, Abiru S, Komori A, et al
    Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response.
    PLoS One. 2015;10:e0129053.
    PubMed     Text format     Abstract available


  324. KERUBO G, Khamadi S, Okoth V, Madise N, et al
    Hepatitis B, Hepatitis C and HIV-1 Coinfection in Two Informal Urban Settlements in Nairobi, Kenya.
    PLoS One. 2015;10:e0129247.
    PubMed     Text format     Abstract available


  325. PFAFFEROTT K, Deshpande P, McKinnon E, Merani S, et al
    Anti-Hepatitis C Virus T-Cell Immunity in the Context of Multiple Exposures to the Virus.
    PLoS One. 2015;10:e0130420.
    PubMed     Text format     Abstract available


  326. MULLHAUPT B, Bruggmann P, Bihl F, Blach S, et al
    Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland.
    PLoS One. 2015;10:e0125214.
    PubMed     Text format     Abstract available


  327. JIANG X, Kanda T, Wu S, Nakamoto S, et al
    Hepatitis C Virus Nonstructural Protein 5A Inhibits MG132-Induced Apoptosis of Hepatocytes in Line with NF-kappaB-Nuclear Translocation.
    PLoS One. 2015;10:e0131973.
    PubMed     Text format     Abstract available


  328. URAKI S, Tameda M, Sugimoto K, Shiraki K, et al
    Substitution in Amino Acid 70 of Hepatitis C Virus Core Protein Changes the Adipokine Profile via Toll-Like Receptor 2/4 Signaling.
    PLoS One. 2015;10:e0131346.
    PubMed     Text format     Abstract available


  329. DOMAGALSKI K, Pawlowska M, Kozielewicz D, Dybowska D, et al
    The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C.
    PLoS One. 2015;10:e0130899.
    PubMed     Text format     Abstract available


  330. LIU S, Chen R, Hagedorn CH
    Tannic Acid Inhibits Hepatitis C Virus Entry into Huh7.5 Cells.
    PLoS One. 2015;10:e0131358.
    PubMed     Text format     Abstract available


  331. PARK EM, Lim YS, Ahn BY, Hwang SB, et al
    AAM-B Interacts with Nonstructural 4B and Regulates Hepatitis C Virus Propagation.
    PLoS One. 2015;10:e0132839.
    PubMed     Text format     Abstract available


  332. MEISSNER EG, Decalf J, Casrouge A, Masur H, et al
    Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.
    PLoS One. 2015;10:e0133236.
    PubMed     Text format     Abstract available


  333. BRAUN DL, Rauch A, Aouri M, Durisch N, et al
    A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
    PLoS One. 2015;10:e0133028.
    PubMed     Text format     Abstract available


  334. GUNDLAPALLI AV, Nelson RE, Haroldsen C, Carter ME, et al
    Correlates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004-2009.
    PLoS One. 2015;10:e0132056.
    PubMed     Text format     Abstract available


  335. MWATELAH RS, Lwembe RM, Osman S, Ogutu BR, et al
    Co-Infection Burden of Hepatitis C Virus and Human Immunodeficiency Virus among Injecting Heroin Users at the Kenyan Coast.
    PLoS One. 2015;10:e0132287.
    PubMed     Text format     Abstract available



  336. Correction: Hepatitis C Virus Nonstructural Protein 5A Inhibits MG132-Induced Apoptosis of Hepatocytes in Line with NF-kappaB-Nuclear Translocation.
    PLoS One. 2015;10:e0134068.
    PubMed     Text format     Abstract available


  337. LIU B, Chen S, Guan Y, Chen L, et al
    Type III Interferon Induces Distinct SOCS1 Expression Pattern that Contributes to Delayed but Prolonged Activation of Jak/STAT Signaling Pathway: Implications for Treatment Non-Response in HCV Patients.
    PLoS One. 2015;10:e0133800.
    PubMed     Text format     Abstract available


  338. KERUBO G, Khamadi S, Okoth V, Madise N, et al
    Correction: Hepatitis B, Hepatitis C and HIV-1 Coinfection in Two Informal Urban Settlements in Nairobi, Kenya.
    PLoS One. 2015;10:e0133342.
    PubMed     Text format     Abstract available


  339. LAMOURY FM, Jacka B, Bartlett S, Bull RA, et al
    The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis.
    PLoS One. 2015;10:e0131437.
    PubMed     Text format     Abstract available


  340. CHEN WC, Tseng CK, Chen YH, Lin CK, et al
    HCV NS5A Up-Regulates COX-2 Expression via IL-8-Mediated Activation of the ERK/JNK MAPK Pathway.
    PLoS One. 2015;10:e0133264.
    PubMed     Text format     Abstract available


  341. HOFMANN WP, Mauss S, Lutz T, Schober A, et al
    Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study.
    PLoS One. 2015;10:e0134839.
    PubMed     Text format     Abstract available


  342. HUEGING K, Weller R, Doepke M, Vieyres G, et al
    Several Human Liver Cell Expressed Apolipoproteins Complement HCV Virus Production with Varying Efficacy Conferring Differential Specific Infectivity to Released Viruses.
    PLoS One. 2015;10:e0134529.
    PubMed     Text format     Abstract available


  343. INSHAW J, Leen C, Fisher M, Gilson R, et al
    The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK.
    PLoS One. 2015;10:e0132772.
    PubMed     Text format     Abstract available


  344. KOVARI H, Russmann S, Ledergerber B, Muller D, et al
    Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
    PLoS One. 2015;10:e0133879.
    PubMed     Text format     Abstract available


  345. AOUDJEHANE L, Bisch G, Scatton O, Granier C, et al
    Infection of Human Liver Myofibroblasts by Hepatitis C Virus: A Direct Mechanism of Liver Fibrosis in Hepatitis C.
    PLoS One. 2015;10:e0134141.
    PubMed     Text format     Abstract available


  346. TACHI Y, Hirai T, Toyoda H, Tada T, et al
    Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus.
    PLoS One. 2015;10:e0133515.
    PubMed     Text format     Abstract available


  347. CHOO MK, El-Bassel N, Adam PC, Gilbert L, et al
    Prevalence and Correlates of HIV and Hepatitis C Virus Infections and Risk Behaviors among Malaysian Fishermen.
    PLoS One. 2015;10:e0118422.
    PubMed     Text format     Abstract available


  348. DOLD L, Ahlenstiel G, Althausen E, Luda C, et al
    Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART).
    PLoS One. 2015;10:e0134158.
    PubMed     Text format     Abstract available


  349. GALLAY PA, Bobardt MD, Chatterji U, Trepanier DJ, et al
    The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.
    PLoS One. 2015;10:e0134707.
    PubMed     Text format     Abstract available


  350. KINKEL HT, Karmacharya D, Shakya J, Manandhar S, et al
    Prevalence of HIV, Hepatitis B and C Infections and an Assessment of HCV-Genotypes and Two IL28B SNPs among People Who Inject Drugs in Three Regions of Nepal.
    PLoS One. 2015;10:e0134455.
    PubMed     Text format     Abstract available



  351. Correction: A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
    PLoS One. 2015;10:e0135547.
    PubMed     Text format     Abstract available


  352. CHEN F, Sun D, Guo Y, Guo W, et al
    Correction: Spatiotemporal Scan and Age-Period-Cohort Analysis of Hepatitis C Virus in Henan, China: 2005-2012.
    PLoS One. 2015;10:e0136333.
    PubMed     Text format     Abstract available


  353. STRASSL R, Rutter K, Stattermayer AF, Beinhardt S, et al
    Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy.
    PLoS One. 2015;10:e0135963.
    PubMed     Text format     Abstract available


  354. WANG Y, McGivern DR, Cheng L, Li G, et al
    Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production.
    PLoS One. 2015;10:e0135232.
    PubMed     Text format     Abstract available


  355. BALAGOPAL A, Barin B, Quinn J, Rogers R, et al
    Immunologic Predictors of Liver Transplantation Outcomes in HIV-HCV Co-Infected Persons.
    PLoS One. 2015;10:e0135882.
    PubMed     Text format     Abstract available


  356. READ SA, Tay ES, Shahidi M, O'Connor KS, et al
    Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response.
    PLoS One. 2015;10:e0136227.
    PubMed     Text format     Abstract available


  357. DO A, Mittal Y, Liapakis A, Cohen E, et al
    Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade.
    PLoS One. 2015;10:e0135645.
    PubMed     Text format     Abstract available


  358. CHEMAITELLY H, Chaabna K, Abu-Raddad LJ
    The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis.
    PLoS One. 2015;10:e0135281.
    PubMed     Text format     Abstract available


  359. ECHEVARRIA D, Gutfraind A, Boodram B, Major M, et al
    Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago.
    PLoS One. 2015;10:e0135901.
    PubMed     Text format     Abstract available


  360. THANAPIROM K, Suksawatamnuay S, Sukeepaisarnjaroen W, Tangkijvanich P, et al
    Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
    PLoS One. 2015;10:e0137365.
    PubMed     Text format     Abstract available


  361. ETIENNE L, Blanchard E, Boyer A, Desvignes V, et al
    The Replacement of 10 Non-Conserved Residues in the Core Protein of JFH-1 Hepatitis C Virus Improves Its Assembly and Secretion.
    PLoS One. 2015;10:e0137182.
    PubMed     Text format     Abstract available


  362. PENG J, Lu Y, Liu W, Zhu Y, et al
    Genotype Distribution and Molecular Epidemiology of Hepatitis C Virus in Hubei, Central China.
    PLoS One. 2015;10:e0137059.
    PubMed     Text format     Abstract available


  363. DALGARD O, Martinot-Peignoux M, Verbaan H, Bjoro K, et al
    The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection.
    PLoS One. 2015;10:e0120866.
    PubMed     Text format     Abstract available


  364. DIETZ J, Susser S, Berkowski C, Perner D, et al
    Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.
    PLoS One. 2015;10:e0134395.
    PubMed     Text format     Abstract available


  365. MOTAWI TK, Shaker OG, El-Maraghy SA, Senousy MA, et al
    Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients.
    PLoS One. 2015;10:e0137706.
    PubMed     Text format     Abstract available


  366. TAMAKI N, Kurosaki M, Higuchi M, Takada H, et al
    Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens.
    PLoS One. 2015;10:e0137351.
    PubMed     Text format     Abstract available


  367. KAUHL B, Heil J, Hoebe CJ, Schweikart J, et al
    The Spatial Distribution of Hepatitis C Virus Infections and Associated Determinants-An Application of a Geographically Weighted Poisson Regression for Evidence-Based Screening Interventions in Hotspots.
    PLoS One. 2015;10:e0135656.
    PubMed     Text format     Abstract available


  368. BARANYI A, Meinitzer A, Breitenecker RJ, Amouzadeh-Ghadikolai O, et al
    Quinolinic Acid Responses during Interferon-alpha-Induced Depressive Symptomatology in Patients with Chronic Hepatitis C Infection - A Novel Aspect for Depression and Inflammatory Hypothesis.
    PLoS One. 2015;10:e0137022.
    PubMed     Text format     Abstract available


  369. ITAKURA J, Kurosaki M, Higuchi M, Takada H, et al
    Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy.
    PLoS One. 2015;10:e0138060.
    PubMed     Text format     Abstract available


  370. YANG CC, Tsai WL, Su WW, Huang CF, et al
    Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.
    PLoS One. 2015;10:e0137852.
    PubMed     Text format     Abstract available



  371. Correction: Correction: Spatiotemporal Scan and Age-Period-Cohort Analysis of Hepatitis C Virus in Henan, China: 2005-2012.
    PLoS One. 2015;10:e0139180.
    PubMed     Text format     Abstract available


  372. LEPIDA A, Colombo M, Fernandez I, Abdurakhmanov D, et al
    Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.
    PLoS One. 2015;10:e0138503.
    PubMed     Text format     Abstract available


  373. COILLY A, Dumortier J, Botta-Fridlund D, Latournerie M, et al
    Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
    PLoS One. 2015;10:e0138091.
    PubMed     Text format     Abstract available


  374. YU G, Chi X, Wu R, Wang X, et al
    Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population.
    PLoS One. 2015;10:e0139015.
    PubMed     Text format     Abstract available


  375. GUTFRAIND A, Boodram B, Prachand N, Hailegiorgis A, et al
    Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections.
    PLoS One. 2015;10:e0137993.
    PubMed     Text format     Abstract available



  376. Correction: Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.
    PLoS One. 2015;10:e0139818.
    PubMed     Text format     Abstract available


  377. SCHMID P, Bregenzer A, Huber M, Rauch A, et al
    Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.
    PLoS One. 2015;10:e0138838.
    PubMed     Text format     Abstract available


  378. NIELSEN MJ, Kazankov K, Leeming DJ, Karsdal MA, et al
    Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients.
    PLoS One. 2015;10:e0137302.
    PubMed     Text format     Abstract available


  379. DENG K, Liu R, Rao H, Jiang D, et al
    Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
    PLoS One. 2015;10:e0138756.
    PubMed     Text format     Abstract available


  380. CHERONI C, Donnici L, Aghemo A, Balistreri F, et al
    Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity.
    PLoS One. 2015;10:e0138546.
    PubMed     Text format     Abstract available


  381. XIE DD, Li J, Chen JT, Eyi UM, et al
    Seroprevalence of Human Immunodeficiency Virus, Hepatitis B Virus, Hepatitis C Virus, and Treponema pallidum Infections among Blood Donors on Bioko Island, Equatorial Guinea.
    PLoS One. 2015;10:e0139947.
    PubMed     Text format     Abstract available


  382. MAAN R, van der Meer AJ, Brouwer WP, Plompen EP, et al
    ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection.
    PLoS One. 2015;10:e0139317.
    PubMed     Text format     Abstract available


  383. LO YC, Tsai MS, Sun HY, Hung CC, et al
    National Trend and Characteristics of Acute Hepatitis C among HIV-Infected Individuals: A Matched Case-Control Study-Taiwan, 2001-2014.
    PLoS One. 2015;10:e0139687.
    PubMed     Text format     Abstract available


  384. TAO J, Liang J, Zhang H, Pei L, et al
    The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China.
    PLoS One. 2015;10:e0140263.
    PubMed     Text format     Abstract available


  385. CHEN SH, Peng CY, Lai HC, Chang IP, et al
    Head-to-Head Comparison between Collagen Proportionate Area and Acoustic Radiation Force Impulse Elastography in Liver Fibrosis Quantification in Chronic Hepatitis C.
    PLoS One. 2015;10:e0140554.
    PubMed     Text format     Abstract available


  386. POIZOT-MARTIN I, Naqvi A, Obry-Roguet V, Valantin MA, et al
    Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients.
    PLoS One. 2015;10:e0141164.
    PubMed     Text format     Abstract available


  387. CHEN AY, Hoare M, Shankar AN, Allison M, et al
    Persistence of Hepatitis C Virus Traces after Spontaneous Resolution of Hepatitis C.
    PLoS One. 2015;10:e0140312.
    PubMed     Text format     Abstract available


  388. CAI Q, Zhang X, Lin C, Shao X, et al
    24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial.
    PLoS One. 2015;10:e0140853.
    PubMed     Text format     Abstract available


  389. STEFAS I, Tigrett S, Dubois G, Kaiser M, et al
    Interactions between Hepatitis C Virus and the Human Apolipoprotein H Acute Phase Protein: A Tool for a Sensitive Detection of the Virus.
    PLoS One. 2015;10:e0140900.
    PubMed     Text format     Abstract available


  390. XU S, Wang Q, Zhang W, Qiu Z, et al
    Seroprevalence of the Hepatitis B, Hepatitis C, and Human Immunodeficiency Viruses and Treponema pallidum at the Beijing General Hospital from 2010 to 2014: A Cross-Sectional Study.
    PLoS One. 2015;10:e0140854.
    PubMed     Text format     Abstract available


  391. BINKA M, Paintsil E, Patel A, Lindenbach BD, et al
    Survival of Hepatitis C Virus in Syringes Is Dependent on the Design of the Syringe-Needle and Dead Space Volume.
    PLoS One. 2015;10:e0139737.
    PubMed     Text format     Abstract available


  392. WADE AJ, Macdonald DM, Doyle JS, Gordon A, et al
    The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service.
    PLoS One. 2015;10:e0142770.
    PubMed     Text format     Abstract available


  393. CHEN M, Ma Y, Chen H, Luo H, et al
    Multiple Introduction and Naturally Occuring Drug Resistance of HCV among HIV-Infected Intravenous Drug Users in Yunnan: An Origin of China's HIV/HCV Epidemics.
    PLoS One. 2015;10:e0142543.
    PubMed     Text format     Abstract available


  394. FENEANT L, Ghosn J, Fouquet B, Helle F, et al
    Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro.
    PLoS One. 2015;10:e0142539.
    PubMed     Text format     Abstract available


  395. GREENAWAY C, Thu Ma A, Kloda LA, Klein M, et al
    The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis.
    PLoS One. 2015;10:e0141715.
    PubMed     Text format     Abstract available


  396. ZHU F, Chen T, Zhang Y, Sun H, et al
    A Novel Adeno-Associated Virus-Based Genetic Vaccine Encoding the Hepatitis C Virus NS3/4 Protein Exhibits Immunogenic Properties in Mice Superior to Those of an NS3-Protein-Based Vaccine.
    PLoS One. 2015;10:e0142349.
    PubMed     Text format     Abstract available


  397. JANSEN K, Thamm M, Bock CT, Scheufele R, et al
    High Prevalence and High Incidence of Coinfection with Hepatitis B, Hepatitis C, and Syphilis and Low Rate of Effective Vaccination against Hepatitis B in HIV-Positive Men Who Have Sex with Men with Known Date of HIV Seroconversion in Germany.
    PLoS One. 2015;10:e0142515.
    PubMed     Text format     Abstract available


  398. VARGAS CL, Espinoza MA, Giglio A, Soza A, et al
    Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naive Patients in Chile.
    PLoS One. 2015;10:e0141660.
    PubMed     Text format     Abstract available


  399. YE F, Xin Z, Han W, Fan J, et al
    Quantitative Proteomics Analysis of the Hepatitis C Virus Replicon High-Permissive and Low-Permissive Cell Lines.
    PLoS One. 2015;10:e0142082.
    PubMed     Text format     Abstract available


  400. FOUQUET B, Ghosn J, Quertainmont Y, Salmon D, et al
    Identification of Variants of Hepatitis C Virus (HCV) Entry Factors in Patients Highly Exposed to HCV but Remaining Uninfected: An ANRS Case-Control Study.
    PLoS One. 2015;10:e0142698.
    PubMed     Text format     Abstract available


  401. AMANZADA A, Reinhardt L, Fey D, Zeisberg EM, et al
    Hepatic Interferon-lambda3 (IFNL3) Gene Expression Reveals Not to Be Attenuated in Non-Favorable IFNL3 rs4803217 or IFNL4 rs368234815 Minor Allele Carriers in Chronic Hepatitis C.
    PLoS One. 2015;10:e0143783.
    PubMed     Text format     Abstract available


  402. SCHEINER B, Mandorfer M, Schwabl P, Payer BA, et al
    The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection.
    PLoS One. 2015;10:e0143429.
    PubMed     Text format     Abstract available


  403. LIMA VD, Rozada I, Grebely J, Hull M, et al
    Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
    PLoS One. 2015;10:e0143836.
    PubMed     Text format     Abstract available


  404. GREENAWAY C, Ma AT, Kloda LA, Klein M, et al
    Correction: The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis.
    PLoS One. 2015;10:e0144567.
    PubMed     Text format     Abstract available


  405. ASSELAH T, Zeuzem S, Soriano V, Bronowicki JP, et al
    ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.
    PLoS One. 2015;10:e0144004.
    PubMed     Text format     Abstract available


  406. REYES-AVILES E, Kostadinova L, Rusterholtz A, Cruz-Lebron A, et al
    Presence of Rheumatoid Factor during Chronic HCV Infection Is Associated with Expansion of Mature Activated Memory B-Cells that Are Hypo-Responsive to B-Cell Receptor Stimulation and Persist during the Early Stage of IFN Free Therapy.
    PLoS One. 2015;10:e0144629.
    PubMed     Text format     Abstract available


  407. MACIAS J, Lopez-Cortes LF, Tellez F, Recio E, et al
    Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    PLoS One. 2015;10:e0143492.
    PubMed     Text format     Abstract available


  408. MUSSINI C, Lorenzini P, Puoti M, Lichtner M, et al
    Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.
    PLoS One. 2015;10:e0140877.
    PubMed     Text format     Abstract available


  409. ABOUT F, Oudot-Mellakh T, Niay J, Rabiega P, et al
    Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.
    PLoS One. 2015;10:e0145105.
    PubMed     Text format     Abstract available


  410. ABOULNASR F, Hazari S, Nayak S, Chandra PK, et al
    IFN-lambda Inhibits MiR-122 Transcription through a Stat3-HNF4alpha Inflammatory Feedback Loop in an IFN-alpha Resistant HCV Cell Culture System.
    PLoS One. 2015;10:e0141655.
    PubMed     Text format     Abstract available


  411. BINKA M, Paintsil E, Patel A, Lindenbach BD, et al
    Correction: Survival of Hepatitis C Virus in Syringes Is Dependent on the Design of the Syringe-Needle and Dead Space Volume.
    PLoS One. 2015;10:e0146088.
    PubMed     Text format     Abstract available


  412. WIEGAND SB, Heidrich B, Susser S, Rogalska-Taranta M, et al
    Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.
    PLoS One. 2015;10:e0145622.
    PubMed     Text format     Abstract available


  413. GEUE C, Wu O, Xin Y, Heggie R, et al
    Cost-Effectiveness of HBV and HCV Screening Strategies - A Systematic Review of Existing Modelling Techniques.
    PLoS One. 2015;10:e0145022.
    PubMed     Text format     Abstract available


  414. FORBI JC, Layden JE, Phillips RO, Mora N, et al
    Next-Generation Sequencing Reveals Frequent Opportunities for Exposure to Hepatitis C Virus in Ghana.
    PLoS One. 2015;10:e0145530.
    PubMed     Text format     Abstract available


  415. SUWANTHAWORNKUL T, Anothaisintawee T, Sobhonslidsuk A, Thakkinstian A, et al
    Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naive Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis.
    PLoS One. 2015;10:e0145953.
    PubMed     Text format     Abstract available


  416. DE MONTEYNARD LA, Dray-Spira R, de Truchis P, Grabar S, et al
    Later cART Initiation in Migrant Men from Sub-Saharan Africa without Advanced HIV Disease in France.
    PLoS One. 2015;10:e0118492.
    PubMed     Text format     Abstract available


  417. HORNER SM, Wilkins C, Badil S, Iskarpatyoti J, et al
    Proteomic analysis of mitochondrial-associated ER membranes (MAM) during RNA virus infection reveals dynamic changes in protein and organelle trafficking.
    PLoS One. 2015;10:e0117963.
    PubMed     Text format     Abstract available


  418. LIU X, Chi X, Gong Q, Gao L, et al
    Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
    PLoS One. 2015;10:e0127518.
    PubMed     Text format     Abstract available


  419. AMORAS EDA S, Gomes ST, Freitas FB, Santana BB, et al
    NGF and P75NTR gene expression is associated with the hepatic fibrosis stage due to viral and non-viral causes.
    PLoS One. 2015;10:e0121754.
    PubMed     Text format     Abstract available


  420. LIN CK, Hung CC, Peng CY, Chao E, et al
    Factors Associated with Methadone Treatment Duration: A Cox Regression Analysis.
    PLoS One. 2015;10:e0123687.
    PubMed     Text format     Abstract available


  421. TIETJEN I, Ntie-Kang F, Mwimanzi P, Onguene PA, et al
    Screening of the Pan-African Natural Product Library Identifies Ixoratannin A-2 and Boldine as Novel HIV-1 Inhibitors.
    PLoS One. 2015;10:e0121099.
    PubMed     Text format     Abstract available


  422. THAKARAR K, Morgan JR, Gaeta JM, Hohl C, et al
    Predictors of Frequent Emergency Room Visits among a Homeless Population.
    PLoS One. 2015;10:e0124552.
    PubMed     Text format     Abstract available


  423. HEIDRICH B, Cordes HJ, Klinker H, Moller B, et al
    Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial.
    PLoS One. 2015;10:e0128069.
    PubMed     Text format     Abstract available


  424. KWON E, Cho JH, Jang HM, Kim YS, et al
    Differential Effect of Viral Hepatitis Infection on Mortality among Korean Maintenance Dialysis Patients: A Prospective Multicenter Cohort Study.
    PLoS One. 2015;10:e0135476.
    PubMed     Text format     Abstract available


  425. NOUBIAP JJ, Aka PV, Nanfack AJ, Agyingi LA, et al
    Hepatitis B and C Co-Infections in Some HIV-Positive Populations in Cameroon, West Central Africa: Analysis of Samples Collected Over More Than a Decade.
    PLoS One. 2015;10:e0137375.
    PubMed     Text format     Abstract available


  426. THEIN HH, Campitelli MA, Yeung LT, Zaheen A, et al
    Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study.
    PLoS One. 2015;10:e0138907.
    PubMed     Text format     Abstract available


  427. WU WP, Chou CT, Chen RC, Lee CW, et al
    Non-Invasive Evaluation of Hepatic Fibrosis: The Diagnostic Performance of Magnetic Resonance Elastography in Patients with Viral Hepatitis B or C.
    PLoS One. 2015;10:e0140068.
    PubMed     Text format     Abstract available


  428. MIGITA K, Komori A, Kozuru H, Jiuchi Y, et al
    Circulating microRNA Profiles in Patients with Type-1 Autoimmune Hepatitis.
    PLoS One. 2015;10:e0136908.
    PubMed     Text format     Abstract available


    January 2014
  429. THIELE M, Gluud LL, Fialla AD, Dahl EK, et al
    Large variations in risk of hepatocellular carcinoma and mortality in treatment naive hepatitis B patients: systematic review with meta-analyses.
    PLoS One. 2014;9:e107177.
    PubMed     Text format     Abstract available


  430. KANAPATHIPILLAI R, McManus H, Kamarulzaman A, Lim PL, et al
    The Significance of HIV 'Blips' in Resource-Limited Settings: Is It the Same? Analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD).
    PLoS One. 2014;9:e86122.
    PubMed     Text format     Abstract available


  431. EGUCHI H, Wada K, Smith DR
    Sociodemographic Factors and Prejudice toward HIV and Hepatitis B/C Status in a Working-Age Population: Results from a National, Cross-Sectional Study in Japan.
    PLoS One. 2014;9:e96645.
    PubMed     Text format     Abstract available


  432. GONCALVES LDA R, Campanhon IB, Domingues RR, Paes Leme AF, et al
    Comparative salivary proteome of hepatitis B- and C-infected patients.
    PLoS One. 2014;9:e113683.
    PubMed     Text format     Abstract available


  433. PEPIN J, Abou Chakra CN, Pepin E, Nault V, et al
    Evolution of the global burden of viral infections from unsafe medical injections, 2000-2010.
    PLoS One. 2014;9:e99677.
    PubMed     Text format     Abstract available


  434. ABDEL-MOHSEN M, Deng X, Danesh A, Liegler T, et al
    Role of MicroRNA Modulation in the Interferon-alpha/Ribavirin Suppression of HIV-1 In Vivo.
    PLoS One. 2014;9:e109220.
    PubMed     Text format     Abstract available


  435. CHRISTIANSEN KM, Mossner BK, Hansen JF, Jarnbjer EF, et al
    Liver Stiffness Measurement among Patients with Chronic Hepatitis B and C: Results from a 5-Year Prospective Study.
    PLoS One. 2014;9:e111912.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: